



Vaccines and Global Health: The Week in Review
19 February 2022 :: Issue 645
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. **This blog allows full text searching of over 23,000 entries.***

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Coronavirus \[COVID-19\] - WHO](#)

:: [Emergencies](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

Milestones - Perspectives

.....
.....

WHO Director-General's remarks at the Munich Security Conference – 18 February 2022

Speech

18 February 2022

[Excerpt]

...Taking those recommendations into account, last month **WHO's Executive Board tasked me with developing a set of proposals on strengthening the global architecture for pandemic prevention, preparedness and response**, to be considered by all Member States at the World Health Assembly in May.

In brief, I see three key pillars of that architecture.

First, we need stronger governance. I think that has been raised by the panelists. Instead of the confusion and incoherence that has fueled this pandemic, we need cooperation and collaboration in the face of common threats, that can address the trust deficit that we have seen.

At a Special Session of the World Health Assembly at the end of last year, WHO's 194 Member States agreed to negotiate a new legally-binding instrument, to set the rules of the game for pandemic prevention, preparedness and response.

WHO also supports the recommendation for a heads of state council, to provide high-level political leadership for rapid and coordinated action. In our view, such a council must be anchored in the constitutional mandate of WHO, to ensure political, strategic and technical coherence.

Second, we need stronger systems and tools to prevent, detect, and respond rapidly to epidemics and pandemics. Already, WHO has taken steps to build some of these systems and tools, including the WHO Hub for Pandemic and Epidemic Intelligence in Berlin, to enhance global surveillance through collaborative intelligence; We're piloting the WHO BioHub System, a new mechanism for countries to share novel biological materials; Several countries are now piloting the Universal Health and Preparedness Review, a new peer-review mechanism for enhancing national preparedness;

We established the ACT Accelerator, which has given us valuable experience and insights into how to fast-track equitable access to countermeasures; And to strengthen capacities for local production of vaccines and other health products in low- and middle-income countries, we have established the WHO Technology Transfer Hub in South Africa, which has now developed its own mRNA COVID-19 vaccine candidate.

Today we announced the first six African countries to receive technology from the hub to produce their own mRNA vaccines: Egypt, Kenya, Nigeria, Senegal, South Africa and Tunisia. But above all, not only the systems and tools, the central point will be developing the workforce. And that is why we are building the WHO Academy in Lyon, France.

And third, we need stronger financing. It's obvious that nationally and globally, we need substantial resources for strengthening global health security. Our analysis estimates the needs at US\$ 31 billion per year.

We estimate that about US\$20 billion could come from existing and projected domestic and international resources, leaving a gap of US\$ 10 billion per year. To close the gap for the most essential functions – such as surveillance, research and market-shaping for countermeasures – we support the idea of a new dedicated financing facility, anchored in, and directed by, WHO's constitutional mandate, inclusive governance and technical expertise.

Any efforts to strengthen the global health security architecture can only succeed if they also strengthen WHO's role at its centre, rather than creating further mechanisms that would only create further fragmentation and potentially leave the world less safe...

.....
.....

BioNTech introduces first modular mRNA manufacturing facility to promote scalable vaccine production in Africa

16 February 2022

:: Developing turnkey solution to enable mRNA-based vaccine production in modular and scalable sites installed by BioNTech

:: **Presidents of Ghana, Rwanda, Senegal, the Director-General of the World Health Organization, the Director of the Africa CDC and the Federal Minister of Economic Cooperation and Development of Germany met in Marburg to jointly discuss the infrastructure, regulatory and technological requirements** to establish end-to-end manufacturing network for mRNA-based vaccines in Africa

:: First manufacturing facility to become a node in a decentralized and robust African end-to-end manufacturing network

:: **Establishment of mRNA manufacturing facilities in Africa is planned in the partner countries Senegal, Rwanda and potentially South Africa**; construction of first facility to start in mid-2022 in first partner country, with the others to follow suit. New project in Ghana to support manufacturing with fill-and-finish capacities

MAINZ, Germany, February 16, 2022 – BioNTech SE has taken a next step to improve vaccine supply in Africa. The company has introduced its approach to establishing scalable vaccine production by developing and delivering turnkey mRNA manufacturing facilities based on a container solution. At a high-level meeting at BioNTech's new manufacturing facility in Marburg and at the invitation of kENUP Foundation, the company presented the container solution named "BioNTainer" to key partners...

The manufacturing solution consists of one drug substance and one formulation module, each called a BioNTainer. Each module is built of six ISO sized containers (2.6m x 2.4m x 12m). This allows for mRNA vaccine production in bulk (mRNA manufacturing and formulation), while fill-and-finish will be taken over by local partners. Each BioNTainer is a clean room which BioNTech equips with state-of-the-art manufacturing solutions. Together, two modules require 800 sqm of space and offer an estimated initial capacity of for example up to 50 million doses of the Pfizer-BioNTech COVID-19 vaccine each year. The BioNTainer will be equipped to manufacture a range of mRNA-based vaccines targeted to the needs of the African Union member

states, for example the Pfizer-BioNTech COVID-19 vaccine and BioNTech's investigational malaria and tuberculosis vaccines, if they are successfully developed, approved or authorized by regulatory authorities.

The capacity can be scaled up by adding further modules and sites to the manufacturing network on the African continent. One of the most critical parts of the manufacturing process is quality control, which includes all necessary tests for each finished vaccine batch. In partnership with local quality control testing labs, BioNTech will help to ensure the identity, composition, strength, purity, absence of product- and process-related impurities, as well as the absence of microbiological contamination of each produced batch.

The establishment of the first mRNA manufacturing facility by BioNTech in the African Union is expected to start in mid-2022. The first BioNTainer is expected to arrive in Africa in the second half of 2022. Manufacturing in the first BioNTainer is planned to commence approximately 12 months after the delivery of the modules to its final location in Africa. BioNTech expects to ship BioNTainers to Rwanda, Senegal and potentially South Africa in close coordination with the respective country and the African Union.

BioNTech will be responsible for the delivery and installation of the modules, while local organizations, authorities and governments will ensure the needed infrastructure. Partners in Ghana and South Africa could support the manufacturing with fill-and-finish capacities. BioNTech will work closely with local authorities to ensure compliance to relevant regulatory procedures of the national regulatory agencies in each partner country, and also coordinate where appropriate with relevant continental and international agencies, including WHO, Africa CDC, the African Medicines Agency (AMA), and the African Union Development Agency (AUDA-NEPAD).

BioNTech will initially staff and operate the facilities to support the safe and rapid initiation of the production of mRNA-based vaccine doses under stringent good manufacturing processes ("GMP") to prepare for the transfer of know-how to local partners to enable independent operation. Vaccines manufactured in these facilities are expected to be dedicated to domestic use and export to other member states of the African Union at a not-for-profit price..

.



Featured Journal Content

Expert Review of Clinical Pharmacology

<https://www.tandfonline.com/journals/ierj20>

Special Report

[WHO collaborative registration procedure using stringent regulatory authorities' medicine evaluation: reliance in action?](#)

Alexandra Vaz et al.

Published online: 12 Feb 2022

<https://doi.org/10.1080/17512433.2022.2037419>

ABSTRACT

Introduction

The regulatory approval of medical products in countries with limited regulatory resources can be lengthy, which often compromises patients' timely access to much-needed medicines. To improve the efficiency of regulatory systems, reliance is being used. Reliance allows an authority to leverage the work performed by other authorities, such as scientific evaluations, to decide on medical products approval within their jurisdiction. This reduces duplication of regulatory efforts, resources and time, while maintaining national sovereignty.

Areas covered

This article analyzes the outcomes and stakeholders' experience of using medicines assessments performed by Stringent Regulatory Authorities (SRA) in the Collaborative Registration Procedures (CRP). Since its establishment in 2015, 59 approvals were granted to 16 medicines in 23 countries through SRA CRP. Results show that the procedure is delivering on the intended benefits of access and speed, with long-term positive impact for resource-limited countries. The article concludes with

recommendations on the need for guidance on management of post-approval changes, wider promotion of the procedure, and increased collaboration between authorities.

Expert opinion

The SRA CRP provides a mechanism for the use of reliance by strengthening communication and promoting the exchange of information among regulators. This fosters faster regulatory approvals and, consequently, earlier access to medicines.

.....
.....
.....

Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

Weekly Epidemiological and Operational updates

Last update: 18 Feb 2022


Confirmed cases :: 418 650 474

Confirmed deaths :: 5 856 224

Vaccine doses administered: 10 279 668 555

.....

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 13 February 2022**



**See [Annex 2: Data, table, and figure notes](#)

Weekly epidemiological update on COVID-19 - 15 February 2022

Overview

During the week of 7 to 13 February 2022, the global number of new COVID-19 cases decreased by 19% as compared to the number reported during the previous week, while the number of new deaths remained similar to that of the previous week. Across the six WHO regions, just over 16 million new

cases and just under 75 000 new deaths were reported. As of 13 February 2022, over 409 million confirmed cases and over 5.8 million deaths have been reported globally.

At the regional level, the Western Pacific Region reported an increase of 19% in the number of new weekly cases while all other regions reported decreases: the South-East Asia Region (37% decrease), the Region of the Americas (32% decrease), the African Region (30% decrease), the European Region (16% decrease) and the Eastern Mediterranean Region (12% decrease). The number of new weekly deaths increased in the Eastern Mediterranean Region (38%), the Western Pacific Region (27%), the African Region (14%) and the Region of the Americas (5%), while it remained similar to that of the previous week in the European Region and decreased in the South-East Asia Region (9%)...

.....
.....

WHO Director General Speeches [selected]

<https://www.who.int/director-general/speeches>

Selected

18 February 2022

Speech

WHO Director-General's remarks at the Munich Security Conference – 18 February 2022

18 February 2022

Speech

WHO Director-General's opening remarks at announcement "spokes" of mRNA technology transfer hub – 18 February 2022

18 February 2022

Speech

WHO Director-General's remarks at thematic roundtable: health systems and vaccine production EU-AU Summit – 18 February 2022

16 February 2022

Speech

WHO Director-General's remarks at Vaccine Equity for Africa – 16 February 2022

14 February 2022

Speech

WHO Director-General's remarks at the COVID-19 Global Action Meeting – 14 February 2022

We're grateful for the leadership of the United States and all countries here today. I've just returned from South Africa yesterday, where I met with President Ramaphosa and saw first-hand the progress underway at the WHO mRNA vaccine technology transfer Hub. The commitment from the government and the private sector is real. This historic initiative comes at a critical time.

In some countries, high vaccine coverage, combined with the lower severity of Omicron, is driving a false narrative that the pandemic is over. At the same time, low vaccine coverage and low testing rates in other countries are creating the ideal conditions for new variants to emerge. **We can bring the pandemic under control this year – but we are at increased risk of squandering that opportunity.**

Currently, 116 countries are off track for our shared target of vaccinating 70% of the population of every country by the middle of this year. Through the ACT Accelerator and the COVAX pillar and our partnership with UNICEF, we are now overcoming some of the supply and delivery constraints we faced last year, with more than 1 billion vaccine doses shipped. In many countries, the issues are not primarily a problem of absorptive capacity. We need to urgently support political leaders to accelerate the rollout of vaccines.

We welcome the ongoing engagement of all countries represented here today, the lines of effort proposed by the United States, and continued alignment with the ACT Accelerator and the African Vaccine Acquisition Trust (AVAT).

Let me leave you with three requests.

First, to vaccinate the world, we ask all countries to support WHO's global target of 70%.

Second, to save lives now, we ask all countries to contribute their fair share to fully fund the ACT Accelerator, especially for the immediate need of US\$ 16 billion.

Third, we need to support models such as the mRNA technology transfer hub in South Africa and its network of spokes around the world, to build capacity for controlling COVID-19 and other preventable diseases.

As I mentioned, I have just witnessed the collaborative work being done at the Hub and by the vaccine developers participating in this historic effort, including Afrigen, Biovac, and the Biomedical Research Institute at Stellenbosch University. Fostering local vaccine manufacturing capacity throughout the globe, supplemented by temporary intellectual property waivers for COVID-19 tools, will help bring this pandemic to an end and keep us all safer.

By working together, across the public and private sectors, we can bring the pandemic under control and drive an inclusive and sustainable recovery...

.....
.....

SAVE THE DATE - Developing a framework for evaluating new COVID-19 vaccines

23 February 2022 13:00 – 19:30 CET

Download Agenda

Registration: https://who-e.zoom.us/webinar/register/WN_MBB2uq8ATsiuG-V2xQSR4w

The WHO R&D Blueprint is organizing a consultation to discuss emerging evidence towards the establishment of correlates of protection for COVID-19 vaccines. There is a global need to increase the supply of vaccines that likely meet the WHO TPP criteria for effectiveness against severe disease. WHO is considering the development of a framework to help evaluate new vaccines, against currently circulating variants or for pan-sarbecovirus vaccines. This may also help inform researchers and developers decisions on how to generate additional data for the assessment of new vaccines. The scientific elements of the proposed framework will be presented and discussed during this meeting.

EPI-WIN webinar: Update on COVID-19 vaccines & vaccine safety monitoring

23 February 2022 14:00 – 15:00 CET

Please join us for a technical briefing on the different types of COVID-19 vaccines and vaccine safety monitoring.

Speakers:

:: Dr. Martin Friede, Unit Head, Vaccine and Immunology Research , WHO

:: Dr Madhava Ram Balakrishnan, Medical Officer, Global Vaccine Safety, WHO

Registratoin: https://who-e.zoom.us/webinar/register/WN_L_tGfKBdSe6ENX7as9NThA

.....
.....

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 23 December 2021

[Full scale view available at title link above]

[Updated on 18 February 2022]

.....

COVID Vaccines/Therapeutics - Developer/Manufacturer Announcements

[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]

AstraZeneca

[Press Releases](#) - No new digest announcements identified

Bharat Biotech

[Press Releases](#) - No new digest announcements identified

BioCubaFarma – Cuba

[Últimas Noticias](#) - No new digest announcements identified

Biontech

[Press Releases](#)

[**BioNTech introduces first modular mRNA manufacturing facility to promote scalable vaccine production in Africa**](#)

16 February 2022

[See Perspectives above for detail]

[**BioNTech to Join High-level Meeting with Partners in Marburg and to Hold Press Conference to Provide an Update on Sustainable Vaccine Manufacturing in Africa**](#)

15 February 2022

CanSinoBIO

[News](#) - *[Website not responding at inquiry]*

Clover Biopharmaceuticals - China

[News](#) - No new digest announcements identified

Curevac [Bayer Ag – Germany]

[News](#)

February 10, 2022

[CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK](#)

Gamaleya National Center

[Latest News and Events](#) - See Russia below

IMBCAMS, China

[Home](#) - Website not responding at inquiry

Janssen/JNJ

[Press Releases](#) - No new digest announcements identified

Moderna

[Press Releases](#)

February 18, 2022

[Moderna Expands Its mRNA Pipeline with Three New Development Programs](#)

:: mRNA-1608 is a vaccine candidate against Herpes simplex virus (HSV)

:: mRNA-1468 is a vaccine candidate against varicella-zoster virus (VZV) to reduce the rate of herpes zoster (shingles)

:: mRNA-4359 is a new checkpoint cancer vaccine

February 16, 2022

[Therapeutic Goods Administration of Australia Authorizes Moderna's Covid-19 Vaccine in Children \(6-11 Years\)](#)

[Moderna Announces Plan to Expand Commercial Footprint in Europe Across Six Additional Countries](#)

[Moderna and ROVI Expand Long-term Collaboration for the Manufacture of MRNA Medicines Over the Next Ten Years](#)

February 15, 2022

[Moderna Announces Plan to Expand Footprint in Asia with Four Additional Subsidiaries](#)

Novavax

[Press Releases](#)

[Health Canada Authorizes Novavax COVID-19 Vaccine](#)

Feb 17, 2022

[Singapore Health Sciences Authority Issues Interim Authorization for Novavax COVID-19 Vaccine](#)

Feb 14, 2022

[Novavax Files for Conditional Marketing Authorization of COVID-19 Vaccine in Switzerland](#)

Feb 14, 2022

Pfizer

[Recent Press Releases](#)

02.15.2022

[European Medicines Agency Approves Pfizer's 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults](#)

Sanofi Pasteur

[Press Releases](#) - No new digest announcements identified

Serum Institute of India

[NEWS & ANNOUNCEMENTS](#) - No new digest announcements identified

Shifa Pharmed [Iran]

<http://shafapharmed.com/>

No news page identified.

Sinopharm/WIBPBIBP

[News](#) - No new digest announcements identified

Sinovac

[Press Releases](#)

[CUHK and SINOVAR Biotech \(Hong Kong\) Limited strategic collaboration framework agreement signing ceremony](#)

2022/02/18

Vector State Research Centre of Virology and Biotechnology

[Home](#) - No new digest announcements identified

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

.....

GSK

[Press releases for media](#)

[GSK provides update on phase III RSV maternal vaccine candidate programme](#)

18 February 2022 GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has voluntarily paused enrolment and vaccination in the GRACE phase III trial (NCT04605159), evaluating its potential respiratory syncytial virus (RSV) maternal vaccine candidate, as well as two other trials investigating this candidate in pregnant women (NCT04980391, NCT05229068).

This decision was made following a recommendation from the Independent Data Monitoring Committee based on an observation from a routine safety assessment. Monitoring safety signals is an integral part of the clinical development process for potential new vaccines...

Merck

[News releases](#) - No new digest announcements identified

Novartis

[News](#) - No new digest announcements identified

SK Biosciences

[Press releases](#) - No new digest announcements identified

Valneva

[Press Releases](#) - No new digest announcements identified

.....
.....

[UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 19 Feb 2022](#)

An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 10/22/2021 reported]




.....
.....

[COVID-19 Global Targets and Progress Tracker - IMF](#)


The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges. The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

Daily Vaccination Rate Needed to Reach 70% by Mid-2022, assuming 2-dose vaccines (per 100 people)



Global COVID-19 Access Tracker

<https://www.covid19globaltracker.org/>




Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 19 Feb 2022]: <https://data.undp.org/vaccine-equity/>

See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)



.....
.....

Duke – Launch and Scale Speedometer

The Race for Global COVID-19 Vaccine Equity

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

[See our COVID Vaccine Purchases research](#)

[See our COVID Vaccine Manufacturing research](#)



[See our COVID Vaccine Donations & Exports research](#)

Overview of donations by top 10 donating countries

Bar chart is ordered by total number of doses pledged.

Donut charts are ordered by proportion of pledged donations shipped.

Country Category:
 Top 10 Donating Countries



Data updated on Feb 11th 2022

Duke | GLOBAL HEALTH
Innovation Center

.....

COVID Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations

COVID-19 Vaccine Roll-out

19 Feb 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

Global COVID-19 Figures: 418M total confirmed cases; 5.9M total confirmed deaths

Global vaccines administered: 10.4B

Number of Countries: 28

COVAX Allocations Round 4-9 (Number of Doses): 170M

COVAX Delivered (Number of Doses): 250M

Other Delivered (Number of Doses): 230M

Total Delivered (Number of Doses): 480M

Total Administered (Number of Doses): 320M

.....

.....


Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]

<https://data.covid19taskforce.com/data>

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed **19 Feb 2022**: <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).



.....
.....

Our World in Data

Coronavirus (COVID-19) Vaccinations [Accessed 19 Feb 2022]

:: [61.9%](#) of the world population has received at least one dose of a COVID-19 vaccine.


:: [10.42 billion doses](#) have been administered globally, and [30.92 million](#) are now administered each day.

:: Only [10.6%](#) of people in low-income countries have received at least one dose.

Share of people who completed the initial COVID-19 vaccination protocol, Feb 14, 2022

Our World
in Data

Total number of people who received all doses prescribed by the initial vaccination protocol, divided by the total population of the country.



Source: Official data collated by Our World in Data - Last updated 15 February 2022, 08:30 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY


Dec 13, 2020 Feb 14, 2022

Share of people who completed the initial COVID-19 vaccination protocol, Feb 14, 2022

Our World
in Data

Total number of people who received all doses prescribed by the initial vaccination protocol, divided by the total population of the country.

+ Add country



Source: Official data collated by Our World in Data - Last updated 15 February 2022, 08:30 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY

Dec 13, 2020 Feb 14, 2022

.....
.....

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

HHS

News

HHS Secretary Xavier Becerra Welcomes Robert Califf Back to HHS as FDA Commissioner

February 17, 2022 | News Release

BARDA – U.S. Department of HHS [to 19 Feb 2022]

<https://aspr.hhs.gov/newsroom/Pages/NewsRoomHome.aspx>

News

DOD Awards Contracts to Purchase COVID-19 Antigen Over-the-Counter Test Kits in Support of POTUS' One Billion Free At-Home COVID-19 Tests

Friday, February 18, 2022

.....

FDA

Press Announcements

No new digest content identified.

Vaccines and Related Biological Products Advisory Committee- FDA

<https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee>

Calendar

Vaccines and Related Biological Products Advisory Committee March 3, 2022 Meeting Announcement - 03/03/2022

.....

White House [U.S.]

Briefing Room – Selected Major COVID Announcements

Letter to the Speaker of the House of Representatives and President of the Senate on the Continuation of the National Emergency Concerning the Coronavirus Disease 2019 (COVID-19) Pandemic

February 18, 2022 • Statements and Releases

Notice on the Continuation of the National Emergency Concerning the Coronavirus Disease 2019 (COVID-19) Pandemic

February 18, 2022 • Presidential Actions

On March 13, 2020, by Proclamation 9994, the President declared a national emergency concerning the coronavirus disease 2019 (COVID-19) pandemic. The COVID-19 pandemic continues to cause significant risk to the public health and safety of the Nation. For this reason, the national emergency declared on March 13, 2020, and beginning March 1, 2020, must continue in effect beyond March 1, 2022. „

Press Briefing by White House COVID-19 Response Team and Public Health Officials

February 16, 2022 • Press Briefings

U.S. Department of State

<https://www.state.gov/coronavirus/releases/>

Media Notes

Special Briefing

Digital Press Briefing with Acting Coordinator for Global COVID-19 Response and Health Security Mary Beth Goodman

Digital Press Briefing with Acting Coordinator for Global COVID-19 Response and Health Security Mary Beth Goodman February 15, 2022

Press Statement

The COVID-19 Global Action Meeting

Antony J. Blinken February 14, 2022

... Participants joining the United States in the COVID-19 Global Action Meeting included the Commonwealth of Australia, Canada, the Republic of Colombia, the French Republic, the Federal Republic of Germany, the Republic of India, the Republic of Indonesia, the Italian Republic, Japan, the Republic of Korea, New Zealand, the Kingdom of Saudi Arabia, the Republic of Senegal, the Republic of South Africa, the Kingdom of Spain, the United Kingdom of Great Britain and Northern Ireland, the African Union/Africa Centres for Disease Control, the European Commission, and the World Health Organization.

.....
.....

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

News & Press Releases

No new digest content identified.

.....

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

Latest Updates [Selected]

Publication

Data collection on COVID-19 outbreaks in closed settings: long-term care facilities, version 2.1

Technical report - 18 Feb 2022

Publication

Evaluation of the SARS-CoV-2 testing policy in Belgium from June to December 2021

Technical report - 14 Feb 2022

.....



European Centre for Disease Prevention and Control

COVID-19 Vaccine Tracker

Cumulative vaccine uptake (%) in the total population in EU/EEA countries

At least one dose	Primary course	Booster/additional dose
74.5%	71.4%	50.3%

Cumulative vaccine uptake (%) in the total population in EU/EEA countries as of 2022-02-18

by reporting week (data for the current week are preliminary)

Accessed 19 Feb 2022

<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

.....

European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

Speech 19 February 2022

[Speech by President von der Leyen at the Munich Security Conference 2022](#)

Statement 18 February 2022

[Statement by President von der Leyen at the joint press conference on the global mRNA technology transfer hub](#)

Statement 16 February 2022

[Statement by President von der Leyen at the 'Vaccine Equity for Africa' launch event, co-organised by BioNTech SE and the kENUP Foundation](#)

Press release 15 February 2022

[Press release on the EU participation to the small group of foreign ministers meeting to coordinate enhanced COVID-19 response](#)

In the COVID-19 Global Action Meeting, convened by US Secretary of State Blinken and gathering the EU, represented by Commissioner Urpilainen, and other partner countries, participants discussed yesterday a 'COVID-19 Global Action Plan'...The EU and its Member States, acting as Team Europe, have been at the fore-front of efforts to tackle the pandemic globally and are committed to co-lead this Global Action Plan, in line with the ongoing Team Europe response to the pandemic. The EU will remain active in all 6 priority areas and specifically offered to co-lead with partners to coordinate actions to tackle vaccine hesitancy and combat disinformation, get shots in arms, bolster supply chain resilience and strengthen the global health security architecture...

.....

.....

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment




Africa CDC Vaccine Dashboard

Africa Vaccinated

Vaccine Administered (Total)	(60.62% of supply)
Partially Vaccinated	(17.34% of population)
Vaccination Completed	(12.13% of population)
Booster Dose	(0.82% of population)

Total of Supply Administered



Vaccines received from COVAX

51

Countries

Vaccines received bilaterally

52

Countries

Vaccines received from AVAT

38

Countries

Accessed 19 Feb 2022. Full scale, interactive dashboard available at:
<https://africacdc.org/covid-19-vaccination/>

.....
.....

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – “the first registered COVID-19 vaccine”

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

[Clinical trials in Russia and Azerbaijan demonstrated safety of AstraZeneca and Sputnik Light vaccines combination](#)

Press release, 14.02.2022

.....
.....

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :
19 February 2022, 08:00
IST (GMT+5:30)

(↑↓ Status change since
yesterday)

Active (0.59%)

253739 (38353↓)

Discharged (98.21%)

42037536 (60298↑)

Deaths (1.19%)

511230 (325↑)

COVID-19 Vaccination
as on : 19 February
2022, 08:00 IST
(GMT+5:30)

Total Vaccination : 1,75,03,86,834 (36,28,578↑)

Government of India – Press Information Bureau

[Latest Press Releases](#)

COVID - 19 Vaccination Update - Day 400

:: India's cumulative vaccination coverage over 175 Crore

:: More than 27 lakh Vaccine doses administered today till 7 pm

Posted On: 19 FEB 2022 8:06PM by PIB Delhi

Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

Press Releases

No new digest content identified.

.....
.....

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Financial Times

19 Feb 2022, p.1

Coronavirus pandemic

Illegal border crossings push Hong Kong Covid outbreak into China

Pressure from Beijing to eradicate outbreak raises prospect of stricter controls

China's rigorous "zero-Covid" policy is facing an unexpected new threat in the form of illegal border crossings by people fleeing a worsening virus outbreak in Hong Kong.

Some Chinese cities have offered rewards for information about people smuggling after 15 individuals illegally entered Zhuhai, in southern Guangdong province, by boat from Hong Kong. At least four of them had Covid-19 and later travelled to other parts of China, according to Chinese media reports.

The cases came in a week when President Xi Jinping said eradicating the outbreak must be Hong Kong's top priority. The local authorities are already weighing mandatory testing for the territory's entire population followed by quarantine for anyone found to be infected.

The prospect of strict controls continuing with no end date is heightening business concern that Hong Kong's position as a financial centre is being hurt by the decision to effectively cut off the territory from the outside world since early in the pandemic.

On Friday, the Chinese government's top representative in Hong Kong summoned real estate tycoons to a meeting at which they discussed contributing hotels, properties and other resources to the effort...

.....
.....
.....

Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

<https://polioeradication.org/polio-today/polio-now/this-week/>

Polio this week as of 16 February 2022

:: During the fourth meeting of the Regional Subcommittee on Polio Eradication and Outbreaks convened on Wednesday 9 February, members issued two statements on Yemen and Afghanistan calling for uninterrupted access for vaccinations to all children and declared the ongoing circulation of any strain of poliovirus in the Region to be a regional public health emergency. [Read more...](#)

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):

- **Djibouti:** two cVDPV2 positive environmental samples
- **Mozambique:** two cVDPV2 cases
- **Nigeria:** 16 cVDPV2 cases and 18 positive environmental samples
- **Somalia:** one cVDPV2 case

.....

Republic of Malawi Reported Confirmed Case of Poliomyelitis

Addis Ababa, Ethiopia- February 18 2022. On 17 February 2022, the Government of Malawi, through the Ministry of Health reported one confirmed case of Poliomyelitis in the country. The Government of Malawi has declared this outbreak as a Public Health Emergency and will activate an Emergency Operations Committee, with the aim of conducting rapid risk assessment and situational analysis. The Government of Malawi has also stated that this is an imported case and there is no evidence of community circulation of the virus. In the absence prompt and effective response, the outbreak has the potential to spread in the country and even beyond borders and could negatively affect the global Polio elimination and eradication agenda...

.....
.....

Disease Outbreak News (DONs)

:: 14 February 2022 | [Lassa Fever - Nigeria](#)

.....
.....

WHO/OCHA Emergencies

Health emergencies list - WHO

"The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences."

[Afghanistan crisis](#) *[Last apparent update: 17 Jan 2022]*

[Crisis in Northern Ethiopia](#) *[Last apparent update: 1 June 2021]*

[Ebola outbreak, Democratic Republic of the Congo, 2021](#) *[Last apparent update: 17 Aug 2021]*

[Ebola outbreak outbreak, N'Zerekore, Guinea, 2021](#) *[Last apparent update: 17 Aug 2021]*

[Coronavirus disease \(COVID-19\) pandemic](#) *[See COVID above]*

[Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020](#)

[Last apparent update: 17 Aug 2021]

[Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020](#)

[Last apparent update: 17 Aug 2021]

[Ebola outbreak, Democratic Republic of the Congo, 2018](#) *[Last apparent update: 24 July 2018]*

[Yemen crisis](#) *[Last apparent update: 12 February 2021]*

[Syria crisis](#) *[Last apparent update: 18 June 2021]*

[Somalia crisis](#) *[Last apparent update: 24 March 2018]*

[Nigeria crisis](#) *[Last apparent update: 1 Oct 2021]*

[Ebola outbreak, Democratic Republic of the Congo, 2017](#) *[Last apparent update: 17 Aug 2021]*

[Zika virus disease outbreak, 2015-2016](#) *[Last apparent update: 24 Jan 2020]*

[Ebola outbreak: West Africa, 2014-2016](#) *[Last apparent update: 17 Aug 2021]*

[Iraq crisis](#) *[Last apparent update: 9 Jan 2008]*

[South Sudan crisis](#) *[Last apparent update: 23 Sep 2020]*

[Avian influenza A \(H7N9\) virus outbreak](#) *[Last apparent update: 13 September 2021]*

[Middle East respiratory syndrome \(MERS-CoV\) outbreak](#) *[Last apparent update: 8 July 2019]*

[Influenza A \(H1N1\) virus, 2009-2010 pandemic](#) [Last apparent update: 10 Aug 2010]

.....

[UN OCHA – Current Emergencies](#)

Current Corporate Emergencies

[Afghanistan](#)

No new updates identified.

[Northern Ethiopia](#)

[Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 17 February 2022](#)

HIGHLIGHTS

- The humanitarian situation in Afar continues to deteriorate with large-scale displacement leading to increased needs while access to many areas is not feasible due to insecurity.
- Additional medical supplies airlifted to Mekelle, but partners are not able to dispatch and distribute them to health facilities across Tigray due to lack of fuel.
- **As part of the second measles campaign in Tigray** last week, more than 60,000 children under five and about 11,000 pregnant and lactating women were screened for malnutrition.
- About 78,000 children and pregnant and lactating women in seven woredas in Afar are currently benefiting from supplementary feeding programs.
- More than 127,000 people reached with food assistance under two food distribution rounds in Amhara during the reporting week.

.....

.....

WHO & Regional Offices [to 19 Feb 2022]

<https://www.who.int/>

News [Selected]

18 February 2022

News release

[WHO announces first technology recipients of mRNA vaccine hub with strong support from African and European partners](#)

[See COVID above for detail]

17 February 2022

Statement

[A € 500 million pledge under the WHO – EIB partnership, with the support of the EU, for health systems in Africa](#)

17 February 2022

Departmental news

[WHO announces the development of new guidance on offering long acting injectable cabotegravir as HIV prevention for people at substantial risk for HIV infection](#)

15 February 2022

Departmental news

WHO collaborative registration procedure using stringent regulatory authorities' medicine evaluation: reliance in action?

[See Featured Journal Content above for detail]

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

17 February 2022 [Malawi declares polio outbreak](#)

WHO Region of the Americas PAHO

:: [PAHO launches 120th Anniversary campaign](#)

Washington D.C. 17 February 2022 (PAHO) – Today, the Pan American Health Organization (PAHO) kicks off its anniversary campaign to celebrate 120 years of active work promoting health and wellbeing throughout the Americas, with a calendar of events set to catalyze dialogue around the region's pressing health challenges. Founded in 1902 under the...

:: [Reduced public health measures contributed to deadly COVID-19 surge in the Americas, PAHO Director says](#)

Deaths rose to 202 people per hour in the Region, despite overall decline in cases. Washington D.C. February 16, 2022 (PAHO) – Complacency around mask wearing, travel, and indoor gatherings created a perfect opportunity for the new Omicron variant to spread rapidly throughout the region and increase deaths, alerted PAHO Director, Carissa F....

:: [PAHO delivers 100 million COVAX vaccine doses to Latin America and the Caribbean](#)

Milestone reached today with delivery of 1.5 million total doses, donated by Spain to Ecuador Washington D.C. 14 February 2022 (PAHO) – The number of doses of COVID-19 vaccine delivered by the Pan American Health Organization (PAHO) to Latin America and the Caribbean reached 100 million today, thanks to the efforts of the organization's...

:: [55% of children and adolescents with cancer recover in Latin America and the Caribbean](#)

PAHO calls for improvements in survival rates. Washington, DC, February 15, 2022 (PAHO)- To mark the International Day against Childhood Cancer, celebrated today, the Pan American Health Organization (PAHO) calls for improvements in survival rates of children and adolescents with cancer, currently at 55% in Latin America and the Caribbean....

WHO South-East Asia Region SEARO

No new digest content identified

WHO European Region EURO

:: [Preparing the next generation of laboratory leaders](#) 16-02-2022

:: [WHO launches fact sheet series on environmental health inequalities in Europe](#) 16-02-2022

:: [Risk remains high in eastern Europe and central Asia with arrival of COVID-19 Omicron variant](#) 15-02-2022

:: [New WHO report highlights scale of childhood cancer inequalities in the European Region](#) 15-02-2022

WHO Eastern Mediterranean Region EMRO

:: [WHO validates the elimination of trachoma as a public health problem in Saudi Arabia](#) 15 February 2022

WHO Western Pacific Region

:: 18 January 2022 [WHO supports whole-of-UN response to volcanic eruption and tsunami in Tonga](#)

.....

WHO Events

<https://www.who.int/news-room/events/2>

[Selected]

WHO Consultation on the Composition of Influenza Virus Vaccines for Use in the 2022-23 Northern Hemisphere Influenza Season

21 – 24 February 2022

SAVE THE DATE - Developing a framework for evaluating new COVID-19 vaccines

23 February 2022 13:00 – 19:30 CET

EPI-WIN webinar: Update on COVID-19 vaccines & vaccine safety monitoring

23 February 2022 14:00 – 15:00 CET

COVID-19 Global Research and Innovation Forum: An invitation to the research community

24 – 25 February 2022

9th ACT-Accelerator Facilitation Council meeting

28 February 2022 12:30 – 15:00 CET

Primary Objectives

- :: To take stock of progress to meet global COVID-19 targets for vaccines, tests, treatments and PPE
- :: Share country experience, lessons learnt and progress in meeting global COVID-19 targets
- :: Reinforce Facilitation Council commitment and political support for the ACT-Accelerator campaign

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected Titles

18 February 2022

WHO Guidelines for malaria

Overview

The WHO Guidelines for malaria bring together the Organization's most up-to-date recommendations for malaria in one user-friendly and easy-to-navigate [online platform](#).

The WHO Guidelines for malaria supersedes 2 previous WHO publications: the Guidelines for the treatment of malaria, third edition and the Guidelines for malaria vector control. Recommendations on malaria will continue to be reviewed and, where appropriate, updated based on the latest available evidence. Any updated recommendations will always display the date of the most recent revision in the MAGICapp platform. With each update, a new PDF version of the consolidated guidelines will also be available for download on the WHO website.

The third version of the Guidelines includes a new section on malaria vaccines and replaces the versions published on 16 February 2021 and 13 July 2021.

17 February 2022

Contact tracing and quarantine in the context of the Omicron SARS-CoV-2 variant: interim guidance

Overview

This interim guidance has been developed in the background of the present global surge of cases due to the SARS-CoV-2 Omicron variant and is meant to be read in conjunction with the current WHO guidance on contact tracing and quarantine. A consolidated contact tracing and quarantine guidance with updated evidence is currently under development, which, when ready, will replace both this CT Omicron interim guidance as well as the current contact tracing and quarantine guidance documents. This Omicron CT interim guidance should also be read in conjunction with the following WHO interim guidance documents...

17 February 2022

Antiretroviral medicines in low- and middle-income countries: forecasts of global and regional demand...

16 February 2022

HIV diagnostic tests in low- and middle-income countries: forecasts of global demand for 2021–2025

16 February 2022

Antiretroviral medicines in low- and middle-income countries: forecasts of global and regional demand...

15 February 2022

Questions and Answers: COVID-19 vaccines and pregnancy

14 February 2022

Public health surveillance for COVID-19: interim guidance

14 February 2022

WHO guideline on control and elimination of human schistosomiasis

.....
.....
.....

CDC/ACIP [U.S.] [to 19 Feb 2022]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases, Announcements [Selected]

CDC Media Telebriefing: COVID-19 Vaccination and Pregnancy

Tuesday, February 15, 2022

.....

ACIP Meetings

Next meeting scheduled for February 23-24, 2022

.....

MMWR News Synopsis Friday, February 18, 2022

Selected Content

- :: Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2022
- :: Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2022
- :: Multistate Outbreak of SARS-CoV-2 B.1.1.529 (Omicron) Variant Infections Among Persons in a Social Network Attending Convention — New York City, November 18–December 20, 2021
- :: Investigation of SARS-CoV-2 Transmission Associated With a Large Indoor Convention — New York City, November–December 2021
- :: Notes from the Field: Outbreak of COVID-19 Among a Highly Vaccinated Population Aboard a U.S. Navy Ship After a Port Visit — Reykjavik, Iceland, July 2021
- :: Previously Released: Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
- :: Previously Released: Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged
- :: Previously Released: Hospitalizations of Children and Adolescents with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, July 2021–January 2022

.....

Coronavirus Disease 2019 (COVID-19)- CDC

Approximately 25 announcements/reports/data summaries.

- 2/18/22 EARLY RELEASE: Pediatric Emergency Department Visits Before and During the COVID-19 Pandemic — United States, January 2019–January 2022
- 2/18/22 Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 18 Feb 2022 06:00:00 EST
- 2/18/22 Steps for Determining Close Contact and Quarantine in K–12 Schools
- 2/17/22 Notes from the Field: Outbreak of COVID-19 Among a Highly Vaccinated Population Aboard a U.S. Navy Ship After a Port Visit — Reykjavik, Iceland, July 2021
- 2/17/22 Investigation of SARS-CoV-2 Transmission Associated With a Large Indoor Convention — New York City, November–December 2021
- 2/17/22 Multistate Outbreak of SARS-CoV-2 B.1.1.529 (Omicron) Variant Infections Among Persons in a Social Network Attending a Convention — New York City, November 18–December 20, 2021
- 2/17/22 Hospitalizations of Children and Adolescents with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, July 2021–January 2022

.....

.....

Africa CDC [to 19 Feb 2022]

<http://www.africacdc.org/>

News

Republic of Malawi Reported Confirmed Case of Poliomyelitis

Addis Ababa, Ethiopia- February 18 2022. On 17 February 2022, the Government of Malawi, through the Ministry of Health reported one confirmed case of Poliomyelitis in the country. The Government of Malawi has declared this outbreak as a Public Health Emergency and will activate an Emergency Operations Committee, with the aim of conducting rapid risk assessment and situational analysis. The Government of Malawi has also stated that this is an imported case and there is no evidence of community circulation of the virus. In the absence prompt and effective response, the outbreak has the potential to spread in the country and even beyond borders and could negatively affect the global Polio elimination and eradication agenda...

Communiqué

Partnership to Accelerate COVID-19 Testing: Scaling up Rapid Antigen Self-testing

17 February 2022

.....
.....

China CDC <http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 19 Feb 2022]

<http://en.nhc.gov.cn/>

News

Feb 19: Daily briefing on novel coronavirus cases in China

On Feb 18, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 137 new cases of confirmed infections.

Central-level agency announced to supervise disease control

Updated: 2022-02-17

chinadaily.com.cn

A central-level disease control and prevention body, which was established amid the COVID-19 pandemic, will take charge of a range of work regarding building the country's emergency response capacity and regular monitoring of public health risks, according to a circular issued on Wednesday.

The document, jointly issued by the general offices of the Communist Party of China Central Committee and the State Council, stipulates that the National Administration of Disease Prevention and Control — the official name of the new agency — will also be tasked to supervise and manage local disease control agencies and disease control work at medical institutions.

Such responsibilities were previously dispersed among several bureaus of the National Health Commission — the country's top health authority.

The commission, a ministerial-level body, will still oversee the newly-established disease control agency, which is designated as being on a vice-ministerial level, according to the circular...

NHC fully supports Hong Kong in countering COVID-19 outbreak

2022-02-17

BEIJING -- China's National Health Commission (NHC) on Thursday said it will continue fully supporting the Hong Kong Special Administrative Region government and meet its demands in containing the current COVID-19 outbreak.

The commission said in a statement on the website that it has been paying close attention to the fifth wave of the COVID-19 pandemic in Hong Kong...

.....

National Medical Products Administration – PRC [to 19 Feb 2022]

<http://english.nmpa.gov.cn/>

News

4.56 million more COVID-19 vaccine doses administered on Chinese mainland

2022-02-17

The number of COVID-19 vaccine doses administered on the Chinese mainland grew by more than 4.56 million on Tuesday, with the total number now over 3.05 billion, data from the National Health Commission showed on Feb 16.

CCDC Weekly Reports: Current Volume (4)

2022-02-18 / No. 7 ONE HEALTH ISSUE

[View PDF of this issue](#)

:: Foreword: Insight on Infectious Diseases from the Perspective of One Health

:: Preplanned Studies: A Landscape Analysis on Virus: based on NCBI Database

.....

.....

.....

Contents [click to move among sections]

::

Contents [click to move among sections]

:: **Coronavirus [COVID-19] - WHO**

:: Emergencies

:: Organization Announcements

:: Journal Watch

Milestones - *Perspectives*

:: Coronavirus [COVID-19] - WHO

:: Emergencies

:: Organization Announcements

:: Journal Watch

.....

.....

.....

Organization Announcements

Editor's Note:

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Airfinity [to 19 Feb 2022]

<https://www.airfinity.com/insights>

INSIGHTS & COMPANY NEWS

No new digest content identified.

Paul G. Allen Frontiers Group [to 19 Feb 2022]

<https://alleninstitute.org/news-press/>

News

[A map of all our brains' blood vessel cells finds new clues to Alzheimer's disease](#)

February 14, 2022

Scientists release the first cell-by-cell atlas of the human blood-brain barrier

BMGF - Gates Foundation [to 19 Feb 2022]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

Press release

Feb 17, 2022

[Bill Gates Meets Prime Minister Imran Khan to Discuss Progress Against Polio, Steps to Overcome Final Challenges to Eradication](#)

SEATTLE (February 17, 2022) – Bill Gates, co-chair of the Bill & Melinda Gates Foundation, today met with Pakistan Prime Minister Imran Khan and other leaders in Islamabad to discuss the country's progress in the effort to stop poliovirus transmission. Pakistan is one of two countries in the world, along with Afghanistan, where wild polio continues to circulate, although not a single child has been paralyzed by the wild polio virus in Pakistan for more than a year...

Press release

Feb 15, 2022

[Ahead of EU–AU Summit, African Medicines Regulators Receive Boost of More Than 100 Million Euros from Team Europe and The Bill & Melinda Gates Foundation](#)

SEATTLE (February 15, 2022) — In a strong endorsement of the work of the African Union Development Agency-NEPAD (AUDA-NEPAD) to strengthen medicines regulators and improve health security on the African continent, the European Union (EU)—including the European Commission, the European Medicines Agency (EMA), and EU member states Belgium, France, and Germany—and the Bill & Melinda Gates Foundation (BMGF) will mobilize more than 100 million euros over the next five years to support the recently established African Medicines Agency (AMA) and other African medicines regulatory initiatives at regional and national levels. This support to strengthen regulatory capacity will improve health security in Africa, including through the expansion of local manufacturing of quality, safe, efficacious, and affordable medicines, vaccines, and other health tools...

Bill & Melinda Gates Medical Research Institute [to 19 Feb 2022]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
No new digest content identified.

CARB-X [to 19 Feb 2022]

<https://carb-x.org/>

News

No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 19 Feb 2022]

<https://centerforvaccineethicsandpolicy.net/>

News/Analysis/Statements

:: **[Informed Consent: A Monthly Review – February 2022](#)** is now posted [here](#)

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

:: **[Statement on ICF \[Informed Consent Form\] Posting for Clinical Trials Involving Gene Editing/Gene Therapies - Invitation to Endorse](#)**

CEPI – Coalition for Epidemic Preparedness Innovations [to 19 Feb 2022]

<http://cepi.net/>

Latest News

[CEPI, Johns Hopkins Center for Health Security, the German Federal Ministry of Education and Research, and the Munich Security Conference Convene Global Actors on Accelerating the Development of Vaccines against Future Pandemic Threats](#)

18 Feb 2022

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 19 Feb 2022]

<https://www.darpa.mil/news>

News

2/16/2022

[DARPA Program to Reduce Mosquito Attraction and Biting Moves into Second Phase](#)

Mosquitoes are vectors of a number of diseases, and are responsible for the majority of insect bites worldwide. The insects are attracted to humans, in part, by chemicals emitted in human breath. It is the heat and volatile molecules from the human skin microbiome, however, that direct mosquitoes to specific feeding sites on the body. The ReVector program aims to precisely, safely, and efficiently reduce mosquito attraction and biting, and, subsequently, to help maintain the health of military personnel operating in disease-endemic regions. In its first phase, ReVector performers developed technologies to modify human skin microbes and modulate the volatiles that these microbiomes

produce. The teams tested petri dish formulations of their modified microbe communities with three mosquito types to gauge changes in attraction.

Duke Global Health Innovation Center [to 19 Feb 2022]

<https://dukeghic.org/>

Our Blog

No new digest content identified.

EDCTP [to 19 Feb 2022]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

17 February 2022

EDCTP joins Europe PubMed Central

EDCTP has become a member of Europe PMC (PubMed Central), an open science platform that maintains a worldwide collection of scientific articles and research outputs. Joining Europe PMC enables EDCTP-funded researchers to share their publications via one central location. Sharing publications by EuropePMC ensures that they will also satisfy the requirements for EDCTP-funded research projects: making publications openly accessible as soon as possible.

Emory Vaccine Center [to 19 Feb 2022]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 19 Feb 2022]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Evidence Aid [to 19 Feb 2022]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

New Resources

**Interleukin-1 blocking agents for treating COVID-19 (search done on 5 November 2021)
Added February 17, 2022**

Fear of needles: possible impact on delivery of vaccines and treatments Added February 15, 2022

Fondation Merieux [to 19 Feb 2022]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 19 Feb 2022]

<https://www.gavi.org/>

News Releases

No new digest content identified.

GHIT Fund [to 19 Feb 2022]

<https://www.ghitfund.org/newsroom/press>

No new digest content identified.

Global Fund [to 19 Feb 2022]

<https://www.theglobalfund.org/en/news/>

News & Stories

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 19 Feb 2022]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 19 Feb 2022]

<http://www.hillemanlabs.org/>

News & Insights

[HILLEMAN VACCINES & BIOLOGICS SYMPOSIUM - 23 February 2022](#)

[agenda](#)

[register](#)

HHMI - Howard Hughes Medical Institute [to 19 Feb 2022]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Vaccines Project [to 19 Feb 2022]

<http://www.humanvaccinesproject.org/>

News

Global COVID Lab Meeting

Feb 24, 2022

[Salim Abdool Karim: Covid-19 in South Africa – an Update on Omicron](#)

HVP COVID Report

Feb 18, 2022

[Kristen Jill Abboud: How Many Doses of COVID-19 Vaccines Are Enough?](#)

IAVI [to 19 Feb 2022]

<https://www.iavi.org/>

Latest News

February 9, 2022

[Meet the IAVI 2022 TB vaccine social media advocacy fellows](#)

Using the power of social media to illuminate the urgent need for sustainable TB vaccine R&D

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 19 Feb 2022]

<http://media.ifrc.org/ifrc/news/press-releases/>

Selected Press Releases, Announcements

17/02/2022

[Solomon Islands: Vaccines vital as COVID overloads Health system](#)

Kuala Lumpur/Honiara/Suva, 17 February 2022 – Ramping up vaccinations is critical in the Solomon Islands as COVID-19 crashes across the country overloading the country's fragile health system from the capital city Honiara to remote islands and villages.

Free of COVID-19 in the community one month ago, the Solomon Islands has reported nearly 5,000 infections and more than 50 deaths. Last week, authorities said one in every two people had COVID-19 symptoms, and testing was overwhelmed, indicating that many more people are sick with the virus...

Institut Pasteur [to 19 Feb 2022]

<https://www.pasteur.fr/en/press-area>

Press Documents

17.02.2022

Legionellosis: a novel mechanism by which the bacterium Legionella pneumophila regulates the immune response of its host cells

16.02.2022

SARS-CoV-2-related viruses capable of infecting human cells discovered in bats in northern Laos

IOM / International Organization for Migration [to 19 Feb 2022]

<http://www.iom.int/press-room/press-releases>

News - Selected

News

18 Feb 2022

COVID-19 Immunization Campaign Targets Mobile Communities Along Gambia-Senegal Border: Over 1,500 Vaccinated

News

18 Feb 2022

IOM Concerned about Increasing Deaths on Greece-Turkey Border

News

17 Feb 2022

UN Secretary-General Launches Report on the Implementation of the Global Compact for Safe, Orderly and Regular Migration

News

16 Feb 2022

IOM Issue Briefs Present a Way Forward on UN Secretary-General's GCM Report Recommendations

ISC / International Science Council [to 19 Feb 2022]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

News Blogs Podcasts

Blogs

Strengthening emergency communications for complex, cascading and compounding events – lessons learned from the Hunga Tonga-Hunga Ha'apai eruption and tsunami in Tonga

14.02.2022

IVAC [to 19 Feb 2022]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

Dr. Rupali Limaye Appointed Deputy Director of IVAC

February 2022

The International Vaccine Access Center (IVAC) is pleased to announce that Rupali Limaye, PhD, MPH, MA, been appointed as its new Deputy Director. Dr. Limaye joined IVAC in 2020 as the Director of Behavioral and Implementation Science and is a full-time faculty member in the Departments of International Health, Epidemiology, and Health, Behavior and Society [...]

IVI [to 19 Feb 2022]

<http://www.ivi.int/>

IVI News & Announcements

IVI named operator of '2022 Global Bio-Intensive Training Courses' by Korean Ministry of Health and Welfare

Institute to run training program on vaccines and biologics development and manufacturing and GxP for 450 trainees from LMICs and Korea
February 16, 2022

Johns Hopkins Center for Health Security [to 19 Feb 2022]

<https://www.centerforhealthsecurity.org/news/center-news/>

Center News

Johns Hopkins Center for Health Security, Coalition for Epidemic Preparedness Innovations, the German Federal Ministry of Education and Research, and the Munich Security Conference Convene Global Actors on Accelerating the Development of Vaccines against Future Pandemic Threats

February 18, 2022

Today, the Johns Hopkins Center for Health Security, the Coalition for Epidemic Preparedness Innovations (CEPI), and the German Federal Ministry of Education and Research convened 9 government officials and 9 technical experts for a tabletop exercise and roundtable discussion on greatly accelerating the development and equitable availability of vaccines against future pandemic threats.

The virtual event, Every Day Counts: A Pandemic Vaccine Exercise, was hosted within the framework of the German G7 Presidency and as an official side event of the 2022 Munich Security Conference. The meeting was a closed-door event for government officials and technical advisors...

Johns Hopkins Center for Health Security Hosts Southeast Asia Strategic Multilateral Biosecurity Dialogue to Explore Lessons from National Pandemic Responses

February 16, 2022

MSF/Médecins Sans Frontières [to 19 Feb 2022]

<http://www.msf.org/>

Latest [Selected Announcements]

Coronavirus COVID-19 pandemic

Protecting people with comorbidities with COVID-19 vaccinations in Khayelitsha

Press Release 17 Feb 2022

- A new vaccination support approach has proven to protect people with comorbidities at higher risk of severe [COVID-19](#) symptoms.

- The targeted approach has seen a significant increase in vaccinations among the community in Khayelitsha.
- MSF has recommended its vaccination support programme to the National Department of Health in order to protect more vulnerable people.

National Academy of Sciences - USA [to 19 Feb 2022]

<http://www.nasonline.org/news-and-multimedia/>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 19 Feb 2022]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 19 Feb 2022]

<http://www.nih.gov/news-events/news-releases>

News Releases

Scientists pinpoint mechanisms associated with severe COVID-19 blood clotting

February 17, 2022 — Researchers found circulating antiphospholipid antibodies, which can be more common among people with autoimmune disorders.

National Science Advisory Board for Biosecurity to convene

February 16, 2022 — Meeting will take place on Monday, Feb. 28, 2022, 12 p.m. - 1 p.m. EST [NIH Videocast](#)

Researchers document third known case of HIV remission involving stem cell transplant

February 15, 2022 — Woman has remained without detectable HIV for 14 months.

OECD [to 19 Feb 2022]

<http://www.oecd.org/newsroom/publicationsdocuments/bydate/>

Newsroom

No new digest content identified.

PATH [to 19 Feb 2022]

<https://www.path.org/media-center/>

Press Releases

Study confirms genetic stability of nOPV2

February 11, 2022 by PATH

nOPV2 is designed to hasten polio eradication

A new study published in npj Vaccines confirms that the novel oral polio vaccine against type 2 polio (nOPV2) is more stable against virulent mutations than the licensed oral polio vaccine against type 2 (OPV2). This is the first study that directly assesses shed nOPV2 virus against shed OPV2 virus in

comparable groups. It adds to the evidence base that the attenuated nOPV2 vaccine is more resistant to reversion than OPV2.

"These findings represent a key milestone in the development of nOPV2," says John Konz, nOPV project director at PATH, which serves as the convener of the nOPV development efforts. "They provide further proof that the designed modifications are working as intended, preventing the primary route by which the currently licensed OPV2 virus becomes more virulent."..

Sabin Vaccine Institute [to 19 Feb 2022]

<http://www.sabin.org/updates/pressreleases>

Statements and Press Releases

No new digest content identified.

UNAIDS [to 19 Feb 2022]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

18 February 2022

[Stronger Africa–Europe partnerships key to advancing education and health rights of adolescent girls in Africa](#)

18 February 2022

[UNAIDS saddened by the death of Joe Muriuki](#)

17 February 2022

[UNAIDS saddened by the death of Leonora Mathe](#)

15 February 2022

[Investments in HIV, health and pandemics are vital for economic recovery in Africa](#)

15 February 2022

[Towards a life of dignity for people living with disabilities](#)

14 February 2022

[Parental consent laws leave adolescents vulnerable to HIV](#)

UNHCR Office of the United Nations High Commissioner for Refugees [to 19 Feb 2022]

<http://www.unhcr.org/en-us/media-centre.html>

Selected News Releases, Announcements

[Thousands of Eritrean refugees displaced in clashes in Ethiopia's Afar region](#)

18 Feb 2022

[UNHCR alarmed by rising violence against displaced civilians in eastern DR Congo](#)

18 Feb 2022

[UNHCR Deputy calls for enhanced access to education and livelihoods for Rohingya refugees in Bangladesh](#)

18 Feb 2022

UNICEF [to 19 Feb 2022]

<https://www.unicef.org/media/press-releases>

Press Releases, News Notes, Statements [Selected]

Statement

02/17/2022

Children in eastern Ukraine must have access to safe education and childhood –UNICEF

Remarks

02/16/2022

UNICEF Executive Director Catherine Russell's remarks at the 2nd Global Disability Summit

As prepared for delivery

Remarks

02/16/2022

UNICEF Executive Director Catherine Russell's remarks at High-Level Briefing on the Secretary-General's Report on the Global Compact for Migration

As prepared for delivery

Press release

02/15/2022

Urgent support needed for 1.4 million children likely to suffer from acute malnutrition in Somalia

Funding immediately needed to procure nutrition supplies and avert deaths

Unitaid [to 19 Feb 2022]

<https://unitaid.org/>

Featured News

No new digest content identified.

USAID [to 19 Feb 2022]

<https://www.usaid.gov/news-information/press-releases/2021>

Selected Press Releases, Statements, Announcements

News

USAID Supports Diaspora-Led Initiatives to Help Address Global Humanitarian Crises

February 17, 2022

Today, the U.S. Agency for International Development (USAID) announced it provided nearly \$2.9 million in FY 2021 funding to support two projects that leverage the unique role of diaspora communities in responding and building resilience to the world's largest humanitarian crises. During a time when humanitarian needs continue to grow globally, USAID recognizes the importance of supporting diaspora-led innovations that bring in new voices, skills, and abilities to save and improve the lives of the world's most vulnerable people.

New Case Studies Show Significant Rise in Vaccination Rates in Sub-Saharan Africa Following U.S. Government's Targeted 'Global VAX' Interventions

February 17, 2022

New case studies from the U.S. Agency for International Development (USAID) show recent targeted efforts to accelerate COVID-19 vaccinations in sub-Saharan Africa are making significant progress. In Côte d'Ivoire, Uganda, and Zambia, United States support contributed to a steady rise in vaccinations—with the most notable increase in Uganda, which in just 6 weeks experienced a 33 percent increase in first-dose shots among the eligible population.

USAID Signs Memorandum of Understanding with Faiths4Vaccines to promote a COVID-19 Year of Action

February 14, 2022

Today, Administrator Samantha Power signed a Memorandum of Understanding (MOU) with Faiths4Vaccines, an inclusive, multifaith movement comprised of local and national religious leaders and medical professionals throughout the United States working together to identify and resolve current gaps in vaccine mobilization, outreach, uptake and ensure equitable distribution. The MOU launches a Year of Action working with civil society, including faith and community partners, on COVID-19 response efforts supported by USAID's Center for Faith-based and Neighborhood Partnerships (FBNP) around the world.

Vaccine Equity Cooperative [nee Initiative] [to 19 Feb 2022]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 19 Feb 2022]

<https://www.vaccineacceptance.org/>

Announcements

No new digest content identified.

Vaccine Confidence Project [to 19 Feb 2022]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children's Hospital of Philadelphia [to 19 Feb 2022]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 19 Feb 2022]

<https://wellcome.ac.uk/news>

News. Opinion, Reports

Explainer

From epidemics to eradication: how the world is ending polio

16 February 2022

The Wistar Institute [to 19 Feb 2022]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 19 Feb 2022]

<https://www.wfpha.org/>

Latest News - Blog

No new digest content identified.

World Bank [to 19 Feb 2022]

<http://www.worldbank.org/en/news/all>

Selected News, Announcements

Keynote Remarks by World Bank Group President David Malpass to the European Union-African Union Summit on Peace, Security and Governance

Thank you, Prime Minister Sanchez, and to the EU and AU for your continued efforts to promote stability and security. The outlook for people in developing countries around the world remains grim – with...

Date: February 17, 2022 Type: Speeches and Transcripts

World Customs Organization – WCO [to 19 Feb 2022]

<http://www.wcoomd.org/>

Latest News – Selected Items

15 February 2022

The HS 2022 version of the COVID-19 reference lists for medical supplies, priority medicines, vaccines and related equipment are now available!

The following lists are available on the [COVID-19 dedicated webpage](#) under WCO instruments and tools:

:: NEW! - [INN List 124 COVID-19 \(Special Edition\)](#)

:: NEW! - [HS Classification reference for COVID-19 medical supplies 3.01 Edition \(2 June 2020\)](#) [es] [ar] [pt] [ru]

:: NEW! - [List of priority medicines for customs during COVID-19 pandemic](#) [ar] [es] [pt] [ru]

The following list is available on the [COVID-19 vaccines distribution webpage](#) under WCO tools and guidance materials:

:: NEW - [HS classification reference for vaccines and related supplies and equipment](#) [ar] [es] [pt] [ru]

World Organisation for Animal Health (OIE) [to 19 Feb 2022]

<https://www.oie.int/en/media/news/>

Press Releases, Statements

No new digest content identified.

WTO - World Trade Organisation [to 19 Feb 2022]

http://www.wto.org/english/news_e/news_e.htm

WTO News and Events

WTO members look at how trade can help LDCs recover from COVID-19

16 February 2022

WTO members noted the sharp decline in least-developed countries' (LDCs) participation in world trade since the outbreak of the COVID-19 pandemic at a meeting of the Sub-Committee on LDCs on 16 February. The chair, Ambassador Kirsti Kauppi (Finland), underlined the need for the international community to work together to promote trade opportunities in LDCs.

WTO, WHO, WIPO to hold workshop on access, use of pandemic-related information resources

14 February 2022

A virtual workshop jointly organized by the World Intellectual Property Organization (WIPO), the World Health Organization (WHO) and the WTO on 28 February will provide an overview of particular COVID-19-related information resources.

The workshop aims to enhance understanding of the characteristics, potential uses and limitations of particular information sources related to COVID-19. A range of experts will discuss information resources containing the following types of data: epidemiological and other health-related issues; clinical trials; technological developments; intellectual property rights (IPRs); and manufacturing and distribution of and access to technologies. Experts will also look at vaccination, diagnostics, treatment rates and cross-border flows of technology.

The workshop responds to the needs of policymakers and other stakeholders working on health, intellectual property and trade issues related to the pandemic, and is specifically targeted at them. The aim of these workshops is to strengthen the capacity of policymakers and experts in members of the three organizations to address the pandemic accordingly. The first in the series of workshops was held on 27 September 2021.

The event is part of the existing collaboration framework between the three organizations, as first highlighted by their Directors-General on 15 June 2021. WIPO Director-General Daren Tang, WHO Director-General Tedros Adhanom Ghebreyesus and WTO Director-General Ngozi Okonjo-Iweala agreed that the three agencies will collaborate on the organization of practical capacity-building workshops at the technical level to enhance the flow of updated information on current developments in the pandemic and responses to achieve equitable access to COVID-19 health technologies.

Registration for the workshop is required and is available [here](#).

The programme of the workshop is available [here](#).

.....

ARM [Alliance for Regenerative Medicine] [to 19 Feb 2022]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 19 Feb 2022]

<https://www.bio.org/press-releases>

Press Releases, Letters, Testimony, Comments [Selected]

BIO Encourages Science-based Oversight for Animal and Plant Biotech as Dr. Califf Takes Helm at FDA

February 15, 2022

The following statement may be attributed to BIO's Vice President for Agriculture and Environment Sarah Gallo: "BIO looks forward to working with a proven leader like Dr. Califf as he takes the helm at FDA. Dr. Califf will lead an agency that contributes to the oversight of animal and plant biotechnology and is indispensable for the safety of our food system..."

New BIO Report Examines the State of Antibacterial Innovation

February 14, 2022

Current pipeline "insufficient" to meet the threat of AMR, policy reforms critically needed The Biotechnology Innovation Organization (BIO) today released a new report examining antibacterial innovation and the current pipeline for new...

DCVMN – Developing Country Vaccine Manufacturers Network [to 19 Feb 2022]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 19 Feb 2022]

<https://internationalbiotech.org/news/>

News

Website in "maintenance mode"

IFPMA [to 19 Feb 2022]

<http://www.ifpma.org/resources/news-releases/>

Selected Press Releases, Statements, Publications

No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest content identified.

International Alliance of Patients' Organizations – IAPO [to 19 Feb 2022]

<https://www.iapo.org.uk/news/topic/6>

Press and media [Selected]

Metrodora Awards Nominations Start - Empower Women Leaders in Science & Medicine

Monday, 14 February 2022

We are delighted to announce the return of the Metrodora Awards, an initiative designed to recognise women leaders and innovators in science and medicine, following the success of the inaugural event in 2020. Women continue to play a leading role in driving scientific and medical breakthroughs...

PhRMA [to 19 Feb 2022]

<http://www.phrma.org/>

Latest News [Selected]

No new digest content identified.

*

*

*

*

Contents [click to move among sections]

::

[Contents \[click to move among sections\]](#)

:: [Coronavirus \[COVID-19\] - WHO](#)

:: [Emergencies](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

Milestones - **Perspectives**

:: [Coronavirus \[COVID-19\] - WHO](#)

:: [Emergencies](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

*

*

*

*

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 13, 2022 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 24, Number 1: E1-105 Jan 2022

<https://journalofethics.ama-assn.org/issue/inequity-along-medicaldental-divide>

Inequity Along the Medical/Dental Divide

Dental and medical health systems in the United States have evolved as fully separate entities. This division exacerbates health inequity, since patients' poor oral health affects their general health. The professionally entrenched view that what's in patients' mouths is somehow isolated from what's going on in the rest of their bodies is one all clinicians need to resist, since this view can be a source of harm, particularly among vulnerable patients and communities. Practical and ethical strategies for better aligning medical and dental goals of care are considered in this issue.

[Reviewed earlier]

American Journal of Infection Control

February 2022 Volume 50 Issue 2 p123-242

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

February 2022 Volume 62 Issue 2 p149-306

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

February 2022 112(2)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 106 (2022): Issue 2 (Feb 2022)

<https://www.ajtmh.org/view/journals/tpmd/106/2/tpmd.106.issue-2.xml>

Perspective Pieces

[Resilient Clinical Trial Infrastructure in Response to the COVID-19 Pandemic: Lessons Learned from the TOGETHER Randomized Platform Clinical Trial](#)

Jamie I. Forrest, Angeli Rawat, Felipe Duailibe, Christina M. Guo, Sheila Sprague, Paula McKay, Gilmar Reis, and Edward J. Mills

Volume/Issue: Volume 106: Issue 2

Article Category: Perspective

DOI: <https://doi.org/10.4269/ajtmh.21-1202>

Articles

Immunogenicity of Oxford-AstraZeneca COVID-19 Vaccine in Vietnamese Health-Care Workers

Nguyen Van Vinh Chau, Lam Anh Nguyet, Nguyen Thanh Truong, Le Mau Toan, Nguyen Thanh Dung, Le Manh Hung, Mai Thanh Nhan, Dinh Nguyen Huy Man, Nghiem My Ngoc, Huynh Phuong Thao, Tran Nguyen Hoang Tu, Huynh Kim Mai, Do Thai Hung, Nguyen Thi Han Ny, Le Kim Thanh, Nguyen To Anh, Nguyen Thi Thu Hong, Le Nguyen Truc Nhu, Lam Minh Yen, Marc Choisy, Tran Tan Thanh, Guy Thwaites, Le Van Tan, and for the Oxford University Clinical Research Unit COVID-19 Research Group
Volume/Issue: Volume 106: Issue 2

Article Category: Research Article

DOI: <https://doi.org/10.4269/ajtmh.21-0849>

Annals of Internal Medicine

February 2022 Volume 175, Issue 2

<http://annals.org/aim/issue>

Original Research

Characteristics and Outcomes of Hospitalized Pregnant Women With Influenza, 2010 to 2019 - A Repeated Cross-Sectional Study

Rachel Holstein, MPH, Fatimah S. Dawood, MD, Alissa O'Halloran, MSPH, Charisse Cummings, MPH, ...
[et al.](#)

Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine - Secondary Analysis of a Randomized Trial

FREE

Deepali Kumar, MD, Victor H. Ferreira, PhD, Victoria G. Hall, MBBS, Queenie Hu, PhD, ...
[et al.](#)

Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels
A Randomized Controlled Trial

Ideas and Opinions

COVID-19 Vaccine Boosters for All Adults: An Optimal U.S. Approach?

FREE

Ameet Sarpatwari, PhD, JD, Ankur Pandya, PhD, Emily P. Hyle, MD, MSc, Govind Persad, JD, PhD

Artificial Intelligence – An International Journal

Volume 303 February 2022

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/302/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 19 Feb 2022)

[No new digest content identified]

BMJ Global Health

February 2022 - Volume 7 - 2

<https://gh.bmj.com/content/7/1>

[Reviewed earlier]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 19 Feb 2022)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 19 Feb 2022)

[COVID-19 vaccine hesitancy among different population groups in China: a national multicenter online survey](#)

COVID-19 vaccine has been available in China since the beginning of the 2021, however, certain numbers of people are reluctant for some reasons to vaccinate. The high vaccine coverage is crucial for controllin...

Authors: Yiman Huang, Xiaoyou Su, Weijun Xiao, Hao Wang, Mingyu Si, Wenjun Wang, Xiaofen Gu, Li Ma, Li Li, Shaokai Zhang, Chunxia Yang, Yanqin Yu and Youlin Qiao

Citation: BMC Infectious Diseases 2022 22:153

Content type: Research article

Published on: 14 February 2022

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 19 Feb 2022)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 19 Feb 2022)

[Mitigating the SARS-CoV-2 Delta disease burden in Australia by non-pharmaceutical interventions and vaccinating children: a modelling analysis](#)

In countries with high COVID-19 vaccination rates the SARS-CoV-2 Delta variant resulted in rapidly increasing case numbers. This study evaluated the use of non-pharmaceutical interventions (NPIs) coupled with ...

Authors: George J. Milne, Julian Carrivick and David Whyatt

Citation: BMC Medicine 2022 20:80

Content type: Research article

Published on: 18 February 2022

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 19 Feb 2022)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 19 Feb 2022)

Stakeholders' hopes and concerns about the COVID-19 vaccines in Southeastern Nigeria: a qualitative study

Equitable access and high uptake of safe and effective vaccines is critical to ending the COVID-19 pandemic. To ensure the success of these vaccines, particularly in many developing and under-developed parts o...

Authors: Uchechukwu Madukaku Chukwuocha, Chiagoziem Ogazirilem Emerole, Greg Ndubeze Iwuoha, Ugonma Winnie Dozie, Princewill Ugochukwu Njoku, Chidinma Onyebuchi Akanazu, Precious Okechukwu Eteike and Charlotte Hemingway

Citation: BMC Public Health 2022 22:330

Content type: Research

Published on: 16 February 2022

The lived experiences of a COVID-19 immunization programme: vaccine hesitancy and vaccine refusal

The COVID-19 pandemic has resulted in a global health emergency and lock-down measures to curb the uncontrolled transmission chain. Vaccination is an effective measure against COVID-19 infections. In Malaysia ...

Authors: Nee Nee Chan, Khang Wei Ong, Ching Sin Siau, Kai Wei Lee, Suat Cheng Peh, Shakila Yacob, Yook Chin Chia, Vei Ken Seow and Pei Boon Ooi

Citation: BMC Public Health 2022 22:296

Content type: Research

Published on: 14 February 2022

BMC Research Notes

<http://www.biomedcentral.com/bmcresearchnotes/content>

(Accessed 19 Feb 2022)

[No new digest content identified]

BMJ Evidence-Based Medicine

February 2022 - Volume 27 - 1

<https://ebm.bmj.com/content/27/1>

[Reviewed earlier]

BMJ Open

February 2022 - Volume 12 - 2

<https://bmjopen.bmj.com/content/12/2>
[Reviewed earlier]

Bulletin of the World Health Organization

Volume 100(2); 2022 Feb 1
<https://www.ncbi.nlm.nih.gov/pmc/issues/399608/>
[Reviewed earlier]

Cell

Feb 17, 2022 Volume 185 Issue 4 p579-746
<https://www.cell.com/cell/current>

Articles

[SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans](#)

Philip A. Mudd, et al.

Analysis of draining lymph nodes of individuals vaccinated with BNT162b2 mRNA vaccine against SARS-CoV-2 identifies viral-spike-specific follicular helper CD4+ T cells that persist for months and contribute to long-term immunity.

Child Care, Health and Development

Volume 48, Issue 2, Pages: 177-357 March 2022
<https://onlinelibrary.wiley.com/toc/13652214/current>
REVIEW ARTICLES

[From research 'on' to research 'with' children about their family lives: A scoping review of ethical and methodological challenges](#)

Anne-Catherine Dubois, Magali Lahaye, Isabelle Aujoulat

Pages: 203-216

First Published: 02 December 2021

Clinical Pharmacology & Therapeutics

Volume 111, Issue 2 Pages: 333-518 February 2022
<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>
[Reviewed earlier]

Clinical Therapeutics

December 2021 Volume 43 Issue 12 p2041-2172
<http://www.clinicaltherapeutics.com/current>
[Reviewed earlier]

Clinical Trials

Volume 19 Issue 1, February 2022
<https://journals.sagepub.com/toc/ctja/19/1>

Design

Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)

Daniel D Murray, Abdel G Babiker, Jason V Baker, Christina E Barkauskas, Samuel M Brown, Christina C Chang, Victoria J Davey, Annetine C Gelijns, Adit A Ginde, Birgit Grund, Elizabeth Higgs, Fleur Hudson, Virginia L Kan, H Clifford Lane, Thomas A Murray, Roger Paredes, Mahesh KB Parmar, Sarah Pett, Andrew N Phillips, Mark N Polizzotto, Cavan Reilly, Uriel Sandkovsky, Shweta Sharma, Marc Teitelbaum, B Taylor Thompson, Barnaby E Young, James D Neaton, Jens D Lundgrenon behalf of the TICO Study Group

First Published October 10, 2021; pp. 52–61

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 19 Feb 2022]

[No new digest content identified]

Contemporary Clinical Trials

Volume 113 February 2022

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/113/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 4, Issue 6 / December 2021

<https://www.liebertpub.com/toc/crispr/4/6>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 9, issue 4, December 2021

<https://link.springer.com/journal/40142/volumes-and-issues/9-4>

[Reviewed earlier]

Current Opinion in Infectious Diseases

February 2022 - Volume 35 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

Developing World Bioethics

Volume 21, Issue 4 Pages: 149-238 December 2021

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 31, Issue 8, 2021

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 15 - Issue 5 - October 2021

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 46, Issue 1 Pages: 1-298 January 2022

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

EMBO Reports

Volume 23 Issue 2 3 February 2022

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 28, Number 2—February 2022

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 37 December 2021

<https://www.sciencedirect.com/journal/epidemics/vol/37/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 150 - 2022

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[New issue; No digest content identified]

Ethics & Human Research

Volume 44, Issue 1 Pages: 1-39 January–February 2022

<https://onlinelibrary.wiley.com/toc/25782363/current>

[Reviewed earlier]

Ethics & International Affairs

Fall 2021 (35.3) | October 2021

<https://www.ethicsandinternationalaffairs.org/2021/fall-2021-35-3/>

The editors of Ethics & International Affairs are pleased to present the Fall 2021 issue of the journal! The highlight of this issue is a book symposium organized by Peter Balint on Ned Dobos's Ethics, Security, and the War Machine, featuring contributions by Peter Balint; Neta C. Crawford; C. A. J. Coady; Ned Dobos; Cécile Fabre; Christopher J. Finlay; David Rodin; and Cheyney Ryan. Additionally, the issue includes a feature article by Philipp Gisbertz-Astolfi on the reduced legal equality of combatants in war and an essay by Hendrik Schopmans and Jelena Cupać on ethical AI, gender equality, and illiberal backlash politics. It also contains a review essay by Andreas Papamichail on the global politics of health security, and a book review by Claire Finkelstein.

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 20 February 2022

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/20/suppl/C>

[New issue; No digest content identified]

The European Journal of Public Health

Volume 32, Issue 1, February 2022

<https://academic.oup.com/eurpub/issue/32/1>

[New issue; No digest content identified]

Expert Review of Vaccines

Vol 21 (1) 2022

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Forum for Development Studies

Volume 48, 2021 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 19 Feb 2022]

[No new digest content identified]

Global Health Action

Volume 15, Issue 1 (2022)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[New issue; No digest content identified]

Global Health: Science and Practice (GHSP)

Vol. 9, No. 4 December 31, 2021

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

[Accessed 19 Feb 2022]

[No new digest content identified]

Global Public Health

Volume 17, Issue 2 (2022)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 19 Feb 2022]

[No new digest content identified]

Health and Human Rights

Volume 23, Issue 2, December 2021

<https://www.hhrjournal.org/volume-23-issue-2-december-2021/>

[Reviewed earlier]

Health Economics, Policy and Law

Volume 17 - Special Issue 1 - January 2022

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

SPECIAL ISSUE: Country Responses to the COVID-19 Pandemic

Articles analyzing country responses in Australia, New Zealand, Canada, U.S., Belgium, Netherlands, Sweden, France, Italy

Health Policy and Planning

Volume 37, Issue 2, February 2022
<https://academic.oup.com/heapol/issue/37/2>
[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 19 Feb 2022]

Rapid research response to the COVID-19 pandemic: perspectives from a National Institute for Health Biomedical Research Centre

With over 5 million COVID-19 deaths at the time of writing, the response of research leaders was and is critical to developing treatments to control the global pandemic. As clinical research leaders urgently r...

Authors: Lorna R. Henderson, Helen McShane and Vasiliki Kiparoglou

Citation: Health Research Policy and Systems 2022 20:24

Content type: Commentary

Published on: 19 February 2022

Human Gene Therapy

Volume 33, Issue 3-4 / February 2022

<https://www.liebertpub.com/toc/hum/33/3-4>

[New issue; No digest content identified]

Humanitarian Practice Network

<https://odihpn.org/>

Online Article

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 17, Issue 11, 2021

<https://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

Immunity

Feb 08, 2022 Volume 55 Issue 2 p185-376

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 19 Feb 2022]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

[Accessed 19 Feb 2022]

[No new digest content identified]

International Health

Volume 14, Issue 1, January 2022

<https://academic.oup.com/inthealth/issue/14/1>

[Reviewed earlier]

International Human Rights Law Review

Volume 10 (2021): Issue 2 (Dec 2021)

<https://brill.com/view/journals/hrlr/10/2/hrlr.10.issue-2.xml>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 9, No 1 (2022) January 2022

<https://www.ijcmph.com/index.php/ijcmph/issue/view/84>

[Reviewed earlier]

International Journal of Epidemiology

Volume 51, Issue 1, February 2022

<https://academic.oup.com/ije/issue>

[New issue; No digest content identified]

International Journal of Human Rights in Healthcare

Volume 14 Issue 5 2021

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/5>

Table of Contents

[Reviewed earlier]

JAMA

February 15, 2022, Vol 327, No. 7, Pages 605-693

<https://jamanetwork.com/journals/jama/currentissue>

Original Investigation

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

Emma K. Accorsi, PhD; Amadea Britton, MD; Katherine E. Fleming-Dutra, MD; et al.

free access has active quiz

JAMA. 2022;327(7):639-651. doi:10.1001/jama.2022.0470

This case-control study uses data from the Centers for Disease Control and Prevention Increasing Community Access to Testing platform to estimate the association between receipt of 3 doses of Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273 vaccine, compared with 2 doses or unvaccinated, and symptomatic SARS-CoV-2 infection, stratified by Omicron and Delta variant.

Editorial

[Booster Vaccination to Prevent COVID-19 in the Era of Omicron An Effective Part of a Layered Public Health Approach](#)

Saad B. Omer, MBBS, MPH, PhD; Preeti N. Malani, MD, MSJ

Research Letter

[Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period](#)

Lindsey Wang; Pamela B. Davis, MD, PhD; David C. Kaelber, MD, PhD, MPH; et al.

free access has active quiz

JAMA. 2022;327(7):678-680. doi:10.1001/jama.2022.0210

This study examines breakthrough SARS-CoV-2 infections, hospitalizations, and mortality in March-August 2021, when the Delta variant predominated, among a general US cohort vaccinated with mRNA-1273 or BNT162b2.

Viewpoint

[COVID-19 Therapeutics for Nonhospitalized Patients](#)

Rajesh T. Gandhi, MD; Preeti N. Malani, MD, MSJ; Carlos del Rio, MD

JAMA. 2022;327(7):617-618. doi:10.1001/jama.2022.0335

This Viewpoint provides a summary of currently available therapeutics for nonhospitalized patients with COVID-19 in the setting of the Omicron variant including principles for equitable allocation.

JAMA Network

[COVID-19 Update February 19, 2022](#)

These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics

February 2022, Vol 176, No. 2, Pages 115-212

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBIR Evidence Synthesis

February 2022 - Volume 20 - Issue 2

<https://journals.lww.com/jbisr/Pages/currenttoc.aspx>

[New issue; No digest content identified]

Journal of Adolescent Health

February 2022 Volume 70 Issue 2 p171-350

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 73 (2022)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Community Health

Volume 47, issue 1, February 2022

<https://link.springer.com/journal/10900/volumes-and-issues/47-1>

[Reviewed earlier]

Journal of Development Economics

Volume 155 March 2022

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/155/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 17 Issue 1-2, February-April 2022

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

February 2022 - Volume 76 - 2

<https://jech.bmj.com/content/76/2>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 14, Issue 4 Pages: 257-345 December 2021

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 17, Issue 3, 2021

<http://www.tandfonline.com/toc/rjge20/current>

Article

[Global health and the COVID-19 pandemic: a care ethics approach](#)

[Fiona Robinson](#)

Pages: 340-352

Published online: 19 Dec 2021

Article

[Intellectual property rights trump the right to health: Canada's Access to Medicines Regime and TRIPs flexibilities in the context of Bolivia's quest for vaccines](#)

James Crombie

Pages: 353-366

Published online: 16 Dec 2021

Article

[The waiver of COVID-19 vaccine patents: a fairness-based approach](#)

Eduardo A. Rueda-Barrera

Pages: 367-374

Published online: 16 Dec 2021

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 33, Number 1, February 2022

<https://muse.jhu.edu/issue/47329>

Table of Contents

Original Papers

[Describing the Epidemiology of COVID-19 in Nigeria: An Analysis of the First Year of the Pandemic](#)

Obinna Oleribe, Olatayo Olawepo, Oliver Ezechi, Princess Osita-Oleribe, Michael Fertleman, Simon D. Taylor-Robinson

pp. 33-46

DOI: [10.1353/hpu.2022.0005](https://doi.org/10.1353/hpu.2022.0005)

Journal of Immigrant and Minority Health

Volume 24, issue 1, February 2022

<https://link.springer.com/journal/10903/volumes-and-issues/24-1>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 20, 2022 _ Issue 1

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 225, Issue 1, 1 January 2022

<https://academic.oup.com/jid/issue/225/1>

[Reviewed earlier]

Journal of Medical Ethics

February 2022 - Volume 48 - 2

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 9, Issue 1 (2022)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

Journal of Pediatrics

February 2022 Volume 241 p1-266

<http://www.jpeds.com/current>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 19 Feb 2022]

[No new digest content identified]

Journal of Public Health Management & Practice

January/February 2022 - Volume 28 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 42, issue 4, December 2021

<https://link.springer.com/journal/41271/volumes-and-issues/42-4>

[Reviewed earlier]

Journal of Refugee & Global Health

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

February 2022 Volume 19 Issue 187

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 29, Issue 1, January 2022

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 96 Number 1 January 2022

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Feb 19, 2022 Volume 399 Number 10326 p695-768, e6

<https://www.thelancet.com/journals/lancet/issue/current>

Comment

[COVID-19 in Europe: new challenges for addressing vaccine hesitancy](#)

Emilie Karafillakis, Pierre Van Damme, Greet Hendrickx, Heidi J Larson

Review

[Diagnostics for COVID-19: moving from pandemic response to control](#)

Rosanna W Peeling, David L Heymann, Yik-Ying Teo, Patricia J Garcia

The Lancet Child & Adolescent Health

Feb 2022 Volume 6 Number 2 p71-136, e5

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Feb 2022 Volume 4 Number 2 e75-e148

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Feb 2022 Volume 10 Number 2 e154-e297

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Feb 2022 Volume 22 Number 2 p151-296, e41-e65

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Feb 2022 Volume 7 Number 2 e93-e194

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Feb 2022 Volume 10 Number 2 p121-220, e11-e24

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 26, issue 2, February 2022

<https://link.springer.com/journal/10995/volumes-and-issues/26-2>

Articles

[Parents' Behaviors and Experiences Associated with Four Vaccination Behavior Groups for Childhood Vaccine Hesitancy](#)

Morgan E. Ellithorpe, Robyn Adams, Fashina Aladé

Content type: OriginalPaper

Published: 07 January 2022

Pages: 280 - 288

Medical Decision Making (MDM)

Volume 42 Issue 2, February 2022

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 99, Issue 4 Pages: 853-1206 December 2021

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Nature

Volume 602 Issue 7897, 17 February 2022

<https://www.nature.com/nature/volumes/602/issues/7897>

Comment | 16 February 2022

[Pandemics disable people — the history lesson that policymakers ignore](#)

Influenza, polio and more have shown that infections can change lives even decades later. Why the complacency over possible long-term effects of COVID-19?

Laura Spinney

Nature Biotechnology

Volume 40 Issue 2, February 2022

<https://www.nature.com/nbt/volumes/40/issues/2>

Patents | 15 February 2022

Recent Orange and Purple Book legislation suggests a need to bridge drug and biologic patent regimes

Additional changes could make the registries of drug patents published by the FDA, called the Orange and Purple Books, more useful and reduce barriers to effective competition from generic and biosimilar drugs.

Bryan S. Walsh, Jonathan J. Darrow, Aaron S. Kesselheim

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 19 Feb 2022)

[No new digest content identified]

Nature Genetics

Volume 54 Issue 2, February 2022

<https://www.nature.com/ng/volumes/54/issues/2>

[Reviewed earlier]

Nature Human Behaviour

Volume 6 Issue 1, January 2022

<https://www.nature.com/nathumbehav/volumes/6/issues/1>

[Reviewed earlier]

Nature Medicine

Volume 28 Issue 1, January 2022

<https://www.nature.com/nm/volumes/28/issues/1>

[Reviewed earlier]

Nature Reviews Genetics

Volume 23 Issue 2, February 2022

<https://www.nature.com/nrg/volumes/23/issues/2>

[Reviewed earlier]

Nature Reviews Immunology

Volume 22 Issue 2, February 2022

<https://www.nature.com/nri/volumes/22/issues/2>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 21 Issue 2, February 2022

<https://www.nature.com/nrd/volumes/21/issues/2>

[Reviewed earlier]

New England Journal of Medicine

February 17, 2022 Vol. 386 No. 7

<https://www.nejm.org/toc/nejm/medical-journal>

Perspective

Health Care Safety during the Pandemic and Beyond — Building a System That Ensures Resilience

L.A. Fleisher, M. Schreiber, D. Cardo, and A. Srinivasan

Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant

R.P. Bhattacharyya and W.P. Hanage

Editorials

The Challenge of Respiratory Syncytial Virus Human Challenge Studies

L.J. Anderson and E.E. Walsh

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 19 Feb 2022]

7, Article number: 19 (2022)

Open access

Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children

Rahnuma Wahid, Laina Mercer, John O. Konz

Abstract

Novel oral poliovirus vaccine type 2 (nOPV2) is being developed to reduce the rare occurrence of disease and outbreaks associated with the genetic instability of the Sabin vaccine strains. Children aged 1 to 5 years were enrolled in two related clinical studies to assess safety, immunogenicity, shedding rates and properties of the shed virus following vaccination with nOPV2 (two candidates) versus traditional Sabin OPV type 2 (mOPV2). The anticipated pattern of reversion and increased virulence was observed for shed Sabin-2 virus, as assessed using a mouse model of poliovirus neurovirulence. In contrast, there were significantly reduced odds of mouse paralysis for shed virus for both nOPV2 candidates when compared to shed Sabin-2 virus. Next-generation sequencing of shed viral genomes was consistent with and further supportive of the observed neurovirulence associated with shed Sabin-2 virus, as well as the reduced reversion to virulence of shed candidate viruses. While shed Sabin-2 showed anticipated A481G reversion in the primary attenuation site in domain V in the 5' untranslated region to be associated with increased mouse paralysis, the stabilized domain V in the candidate viruses did not show polymorphisms consistent with reversion to neurovirulence. The available data from a key target age group for outbreak response confirm the superior genetic and phenotypic stability of shed nOPV2 strains compared to shed Sabin-2 and suggest that nOPV2 should be associated with less paralytic disease and potentially a lower risk of seeding new outbreaks.

Pediatrics

Volume 149, Issue 2, February 1, 2022

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

PharmacoEconomics

Volume 40, issue 2, February 2022

<https://link.springer.com/journal/40273/volumes-and-issues/40-2>

[New issue; No digest content identified]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 19 Feb 2022)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 19 Feb 2022)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 19 Feb 2022)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 19 Feb 2022)

[Vietnam: Neglected tropical diseases in an emerging and accelerating economy](#)

Kala Pham, Peter J Hotez

Viewpoints | published 17 Feb 2022 PLOS Neglected Tropical Diseases

<https://doi.org/10.1371/journal.pntd.0010140>

PLoS One

<http://www.plosone.org/>

[Accessed 19 Feb 2022]

Research Article

[Media attention and Vaccine Hesitancy: Examining the mediating effects of Fear of COVID-19 and the moderating role of Trust in leadership](#)

Lulin Zhou, Sabina Ampon-Wireko, Xinglong Xu, Prince Edwudzie Quansah, Ebenezer Larnyo

Research Article | published 18 Feb 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0263610>

[Infection and vaccination status of COVID-19 among healthcare professionals in academic platform: Prevision vs. reality of Bangladesh context](#)

Bilkis Banu, Nasrin Akter, Sujana Haque Chowdhury, Kazi Rakibul Islam, Md. Tanzeerul Islam, Sarder Mahmud Hossain
Research Article | published 18 Feb 2022 PLOS ONE
<https://doi.org/10.1371/journal.pone.0263078>

Hepatitis vaccination adherence and completion rates and factors associated with low compliance: A claims-based analysis of U.S. adults

Joyce LaMori, Xue Feng, Christopher D. Pericone, Marco Mesa-Frias, Obiageli Sogbetun, Andrzej Kulczycki
Research Article | published 17 Feb 2022 PLOS ONE
<https://doi.org/10.1371/journal.pone.0264062>

Determinants of vaccine coverage and timeliness in a northern Pakistani village

Alexandra F. Jamison, Benjamin J. J. McCormick, Ejaz Hussain, Elizabeth D. Thomas, Syed Iqbal Azam, Chelsea L. Hansen, Zeba A. Rasmussen
Research Article | published 17 Feb 2022 PLOS ONE
<https://doi.org/10.1371/journal.pone.0263712>

To vax or not to vax: Predictors of anti-vax attitudes and COVID-19 vaccine hesitancy prior to widespread vaccine availability

Hannah A. Roberts, D. Angus Clark, Claire Kalina, Carter Sherman, Sarah Brislin, Mary M. Heitzeg, Brian M. Hicks
Research Article | published 15 Feb 2022 PLOS ONE
<https://doi.org/10.1371/journal.pone.0264019>

Vaccination-related attitudes and behavior across birth cohorts: Evidence from Germany

Claudia Diehl, Christian Hunkler
Research Article | published 14 Feb 2022 PLOS ONE
<https://doi.org/10.1371/journal.pone.0263871>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 19 Feb 2022]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

January 25, 2022; vol. 119 no. 4

<https://www.pnas.org/content/119/4>

[New issue; No digest content identified]

Prehospital & Disaster Medicine

Volume 37 - Issue 1 - February 2022

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[New issue; No digest content identified]

Preventive Medicine

Volume 155 February 2022

<https://www.sciencedirect.com/journal/preventive-medicine/vol/155/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

09 February 2022 Volume 289 Issue 1968

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 203 Pages 1-130 (February 2022)

<https://www.sciencedirect.com/journal/public-health/vol/203/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 14, Issue 3, November 2021

<http://phe.oxfordjournals.org/content/current>

[New issue; No digest content identified]

Public Health Reports

Volume 137 Issue 1, January/February 2022

<https://journals.sagepub.com/toc/phrg/137/1>

[Reviewed earlier]

Qualitative Health Research

Volume 32 Issue 3, February 2022

<https://journals.sagepub.com/toc/qhra/current>

[Reviewed earlier]

Research Ethics

Volume 18 Issue 1, January 2022

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 19 Feb 2022]

[No new digest content identified]

**Revista Panamericana de Salud Pública/Pan American Journal of Public Health
(RPSP/PAJPH)**

<https://www.paho.org/journal/en>

Selected Articles

[No new digest content identified]

Risk Analysis

Volume 42, Issue 1 January 2022

<https://onlinelibrary.wiley.com/toc/15396924/current>

Special Issue: Global Systemic Risk and Resilience for Novel Coronavirus in Post-Pandemic Era

EDITORIAL

Free Access

[Global systemic risk and resilience for novel coronavirus in postpandemic era](#)

Desheng Dash Wu, Jade Mitchell, James H. Lambert

Pages: 1-4

First Published: 12 February 2022

Original Research Articles

[Effectiveness of Emergent Ad Hoc Coordination Groups in Public Health Emergencies](#)

Yushim Kim, Kangbae Lee, Seong Soo Oh, Heejin Park

Pages: 5-20

First Published: 07 May 2021

[A Pandemic Risk Perception Scale](#)

Kelmara Mendes Vieira, Ani Caroline Grigion Potrich, Aureliano Angel Bressan, Leander Luiz Klein, Breno Augusto Diniz Pereira, Nelson Guilherme Machado Pinto

Pages: 69-84

First Published: 10 August 2021

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 19 Feb 2022]

[No new digest content identified]

Science

Volume 375| Issue 6582| 18 Feb 2022

<https://www.science.org/toc/science/current>

Editorial

[Empower with evidence](#)

Susan G. Amara

[Excerpt]

This week (17 to 20 February), the virtual annual meeting of the American Association for the Advancement of Science (AAAS, the publisher of *Science*) will address the challenges of building the

public's trust and understanding of science by illuminating both great science and innovative initiatives in advocacy, education, and policy. The theme, "Empower with Evidence," speaks to the critical importance of decision-making, policy-making, and interventions that are grounded in knowledge and facts, not opinions—or worse, misinformation.

The ability of science to transform the world is increasingly threatened by misinformation that is jeopardizing trust in science. As highlighted [in *Science* last week](#), the world's information ecosystem is rapidly changing, and online environments have become a powerful open marketplace of facts, ideas, and opinions—where the meaningfulness of science is easily drowned out by the noise.

Solutions to this dilemma include training students and professional scientists to more effectively translate their work to the public, harnessing insights from the behavioral and social sciences to better engage with the public, and working with social media platforms to improve information delivery to a broader audience. These are important efforts, but do they get to the root of the problem?...

Policy Forum

Sovereignty, sanctions, and data sharing under international law

BY Michelle Rourke, Mark Eccleston-Turner, Stephanie Switzer

17 Feb 2022: 724-726

Pathogen samples and scientific data are bargaining chips in a global argument about who gets what in a pandemic

Abstract

In September 2021, after inaugurating the Berlin-based World Health Organization (WHO) Hub for Pandemic and Epidemic Intelligence, German Health Minister Jens Spahn indicated that sanctions might be an appropriate tool to deal with WHO member states that do not cooperate on data sharing during disease outbreaks. Tedros Adhanom Ghebreyesus, director general of the WHO, affirmed this, stating that "exploring the [idea of] sanctions may be important" in cases where collaboration fails ([1](#)). Such comments indicate that the WHO Hub has been designed without much consideration of data sovereignty and "access and benefit sharing" (ABS) debates occurring across multiple United Nations (UN) bodies, including the WHO. Threats of sanctions do little to promote the ideals of equity and solidarity often touted as foundational to global health governance. They entrench the idea that pathogen samples and associated data are "bargaining chips" rather than vital inputs to public health research and pandemic response.

Science Translational Medicine

Volume 14| Issue 632| 16 Feb 2022

<https://www.science.org/toc/stm/current>

Editorial

Translating science to medicine: The case for physician-scientists

BY Paul J. Utz, et al.

16 Feb 2022

FULL ACCESS

As the number of physician-scientists continues to decline, action must be taken to support them as they embark on their careers.

Social Science & Medicine

Volume 292 January 2022

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/292/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 19 Feb 2022]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 42, issue 3-4, August 2021

<https://link.springer.com/journal/11017/volumes-and-issues/42-3>

Special Issue: A plea for an experimental philosophy of medicine

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 45 January–February 2022

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/45/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 27, Issue 2 Pages: i-iv, 121-216 February 2022

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 40, Issue 5 Pages 691-832 (31 January 2022)

<https://www.sciencedirect.com/journal/vaccine/vol/40/issue/5>

Short communication Full text access

[Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents](#)

Young June Choe, Seonju Yi, Insob Hwang, Jia Kim, ... Eun Hwa Choi

Pages 691-694

Research article Open access

[Impact of the COVID-19 pandemic on pediatric and adolescent vaccinations and well child visits in the United States: A database analysis](#)

Stephanie A. Kujawski, Lixia Yao, H. Echo Wang, Cristina Carias, Ya-Ting Chen

Pages 706-713

Research article Open access

[Optimizing vaccine distribution via mobile clinics: a case study on COVID-19 vaccine distribution to long-term care facilities](#)

Samta Shukla, Francois Fressin, Michelle Un, Henriette Coetzer, Sreekanth K. Chaguturu

Pages 734-741

Research article Abstract only

Vaccine timeliness and prevalence of undervaccination patterns in children ages 0–19 months, U.S., National Immunization Survey-Child 2017

Rain E. Freeman, Juthika Thaker, Matthew F. Daley, Jason M. Glanz, Sophia R. Newcomer
Pages 765-773

Value in Health

February 2022 Volume 25 Issue 2 p161-320
<https://www.valueinhealthjournal.com/current>
[Reviewed earlier]

.....
.....

Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 19 Feb 2022]

Research Article metrics

Revised

Setting up child health and mortality prevention surveillance in Ethiopia [version 2; peer review: 1 approved, 1 approved with reservations]

Anna C. Seale, Nega Assefa, Lola Madrid, Stefanie Wittmann, Hanan Abdurahman, Nardos Teferi, Letta Gedefa, Alexander Mohamed, Natnael Debela, Tseyon Tesfaye, Tigistu Samuel, Mehret Dubale, Hiwot Yigzaw, Eyoel Taye, Workalemahu Bekele, Caroline Ackley, Gutema Imana Keno, Yosef Zegeye, Zerihun Girma, Ketema Degefa, Berhanu Damisse, Adugna Tadesse, Mohammed Aliyi, Gurmu Feyissa, Yenenesh Tilahun, Getahun Wakwaya, Bizunesh Sintayehu, Getamesay Abayneh, Addisu Alemu, Emmanuel Azore, Joe Oundo, Zelalem T Mariam, Dadi Marami, Mulu Berihun, Mussie Berhanu, Mahlet Mekonnen, Andualem Alemayehu, Nana Sarkodie-Mensah, Shirine Voller, Boniface Jibendi, Abraham Aseffa, Taye Balcha, Robert F. Breiman, Scott Dowell, Asnake Worku, Tsigereda Kifle, Ebba Abate, Yadeta Dessie, J. Anthony G. Scott

Peer Reviewers Godfrey M. Bigogo; Bernt Lindtjørn

Funders

Bill and Melinda Gates Foundation

Wellcome

LATEST VERSION PUBLISHED 14 Feb 2022

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

Adolescent vaccination with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine and effectiveness against COVID-19: national test-negative case-control study, England

Annabel A Powell, Freja Kirsebom, Julia Stowe, Kelsey McOwat, Vanessa Saliba, Mary E Ramsay, Jamie Lopez Bernal, Nick Andrews, Shamez N Ladhani

medRxiv 2021.12.10.21267408; doi: <https://doi.org/10.1101/2021.12.10.21267408>

Meta-analyses on SARS-CoV-2 Viral Titers in Wastewater and Their Correlations to Epidemiological Indicators

David Mantilla-Calderon, Kaiyu (Kevin) Huang, Aojie Li, Kaseba Chibwe, Xiaoqian Yu, Yinyin Ye, Lei Liu, Fangqiong Ling

medRxiv 2022.02.14.22270937; doi: <https://doi.org/10.1101/2022.02.14.22270937>

City-wide wastewater genomic surveillance through the successive emergence of SARS-CoV-2 Alpha and Delta variants

F.S. Brunner, M.R. Brown, I. Bassano, H. Denise, M.S. Khalifa, M. Wade, J.L. Kevill, D.L. Jones, K. Farkas, A.R. Jeffries, The COVID-19 Genomics UK (COG-UK) Consortium, E. Cairns, C. Wierzbicki, S. Paterson

medRxiv 2022.02.16.22269810; doi: <https://doi.org/10.1101/2022.02.16.22269810>

Racial discrimination, low trust in the health system, and COVID-19 vaccine uptake: a longitudinal observational study of 633 UK adults from ethnic minority groups

Elise Paul, Daisy Fancourt, Mohammad Razai

medRxiv 2021.08.26.21262655; doi: <https://doi.org/10.1101/2021.08.26.21262655>

SARS-CoV-2 infection in Africa: A systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021

HC Lewis, H Ware, M Whelan, L Subissi, Z Li, X Ma, A Nardone, M Valenciano, B Cheng, K Noel, C Cao, M Yanes-Lane, B Herring, A Talisuna, N Nsenga, T Balde, DA Clifton, M Van Kerkhove, DL Buckeridge, N Bobrovitz, J Okeibunor, RK Arora, I Bergeri, the UNITY Studies Collaborator Group

medRxiv 2022.02.14.22270934; doi: <https://doi.org/10.1101/2022.02.14.22270934>

Assessing the Profile of Unvaccinated COVID-19 Individuals in African American and Latinx Communities in Eastern Pennsylvania

Kenya M. Colvin, Kennedy S. Camara, Latasha S. Adams, Adline P. Sarpong, Danielle G. Fuller, Sadie E. Peck, Anthony S. Ramos, Ariana L. Acevedo, Meless A. Badume, Shae-lyn A. Briggs, Tiffany N. Chukwurah, Zanett Davila-Gutierrez, James A. Ewing, Jemimah O. Frempong, Amirah A. Garrett, Steven J. Grampp, Jahasia W. Gillespie, Emmanuel J. Herrera, Emis J. Maddox, John C. Pelaez, Olivia L. Quartey, Fanny Rodriguez, Luis A. Vasquez, Brian J. Piper, Swathi Gowtham

medRxiv 2022.02.11.22270504; doi: <https://doi.org/10.1101/2022.02.11.22270504>

Co-infection with SARS-COV-2 Omicron and Delta Variants Revealed by Genomic Surveillance

Rebecca J Rockett, Jenny Draper, Mailie Gall, Eby M Sim, Alicia Arnott, Jessica E Agius, Jessica Johnson-Mackinnon, Elena Martinez, Alexander P Drew, Clement Lee, Christine Ngo, Marc Ramsperger, Andrew N Ginn, Qinning Wang, Michael Fennell, Danny Ko, Linda Huston, Lukas Kairaitis, Edward C Holmes, Matthew N O'Sullivan, Sharon C-A Chen, Jen Kok, Dominic E Dwyer, Vitali Sintchenko

medRxiv 2022.02.13.22270755; doi: <https://doi.org/10.1101/2022.02.13.22270755>

Unpacking COVID-19 and Conspiracy Theories in the UK Black Community

Tushna Vandrevalla, Jane Hendy, Kristin Hanson, Lailah Alidu, Aftab Ala
medRxiv 2022.02.12.22270438; doi: <https://doi.org/10.1101/2022.02.12.22270438>

Wellcome Open Research [to 19 Feb 2022]

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 19 Feb 2022]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

Research Article metrics

Revised

Date of introduction and epidemiologic patterns of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Mogadishu, Somalia: estimates from transmission modelling of satellite-based excess mortality data in 2020 [version 2; peer review: 1 approved, 1 approved with reservations]

Mihaly Koltai, Abdihamid Warsame, Farah Bashiir, Terri Freemantle, Chris Reeve, Chris Williams, Mark Jit, Stefan Flasche, Nicholas G. Davies, CMMID COVID-19 working group, Ahmed Aweis, Mohamed Ahmed, Abdirisak Dalmar, Francesco Checchi

Peer Reviewers Zindoga Mukandavire; Bhaswar Ghosh

Funders

Wellcome Trust

Foreign, Commonwealth and Development Office

UK Research and Innovation

LATEST VERSION PUBLISHED 18 Feb 2022

Systematic Review metrics AWAITING PEER REVIEW

Influences on User Trust in Healthcare Artificial Intelligence: A Systematic Review [version 1; peer review: awaiting peer review]

Eva Jermutus, Dylan Kneale, James Thomas, Susan Michie

Peer Reviewers Invited

Funders

Wellcome Trust

Economic and Social Research Council

PUBLISHED 18 Feb 2022

Research Article metrics

Revised

Lessons learned and lessons missed: impact of the coronavirus disease 2019 (COVID-19) pandemic on all-cause mortality in 40 industrialised countries and US states prior to mass vaccination [version 2; peer review: 1 approved, 1 approved with reservations]

Vasilis Kontis, James E. Bennett, Robbie M. Parks, Theo Rashid, Jonathan Pearson-Stuttard, Perviz Asaria, Bin Zhou, Michel Guillot, Colin D. Mathers, Young-Ho Khang, Martin McKee, Majid Ezzati

Peer Reviewers Rajeev Gupta; Virgilio Gómez-Rubio

Funders

Wellcome Trust
British Heart Foundation
US Environmental Protection Agency
LATEST VERSION PUBLISHED 15 Feb 2022

* * * *

Think Tanks

Brookings

<http://www.brookings.edu/>

Accessed 19 Feb 2022

How We Rise

The pandemic showed why social and structural determinants of health matter. Now it's time for policymakers to act.

Anthony Barr and Ariel Gelrud Shiro

Friday, February 18, 2022

Future Development

Harnessing technology for pandemic preparedness demands system reform

Yolanda Botti-Lodovico

Friday, February 18, 2022

Africa in Focus

What's next for R&D in health for Africa?

Dr. Christian Happi

Thursday, February 17, 2022

Future Development

Getting out of the coronavirus economic contraction

Indermit Gill, M. Ayhan Kose, and Dana Vorisek

Wednesday, February 16, 2022

Africa in Focus

The future of vaccine manufacturing in Africa

Chidi Victor Nweneka and Tolu Disu

Monday, February 14, 2022

Center for Global Development [to 19 Feb 2022]

<https://www.cgdev.org/>

Accessed 19 Feb 2022

Operationalizing the African Medicines Agency: The Strategic Design of a Regional Platform for Medicines Regulation

Event 2/24/22

As of November 5, 2021, the African Union signed into force its second specialized health agency: the African Medicines Agency (AMA). More than two years after its introduction, the [AMA treaty](#) has

now been ratified by 17 African Union member countries – two more than was required – and has been signed by many more, making it the latest regional partnership to strengthen capacity for medicines regulation and facilitate regulatory harmonization across the African continent in order to improve access to safe, effective, and quality-assured medicines. With high-level support secured, attention now must shift to strategic questions of how to operationalize the AMA and set it up for success.

African Vaccine Manufacturing with EU support: Addressing Demand Uncertainties is Crucial for Success

February 15, 2022

Last week, the European Union and its member states placed a “European global health strategy” at the top of their shared agenda. And as part of the EU-Africa summit this week in Brussels, the EU is highlighting its support for regional manufacturing of COVID-19 vaccine via the African Union’s Partnership for African Vaccine Manufacturing (PAVM) as a major piece of the overall agenda.

[Amanda Glassman](#) and [Prashant Yadav](#)

Decolonising EU-Africa Relations Is A Pre-Condition For A True Partnership Of Equals

February 15, 2022

The upcoming EU-Africa summit is a welcome step towards upgrading ties. But a true partnership of equals between the two continents requires a decolonization of relations between the EU and Africa.

[Shada Islam](#)

Chatham House [to 19 Feb 2022]

<https://www.chathamhouse.org/>

Accessed 19 Feb 2022

[No new digest content identified]

CSIS

<https://www.csis.org/>

Accessed 19 Feb 2022

Upcoming Event

Overcoming Gender-Related Barriers to Immunization Services

March 8, 2022

Kaiser Family Foundation

https://www.kff.org/search/?post_type=press-release

Accessed 19 Feb 2022

February 17, 2022 *News Release*

Analysis Finds The Share of Nursing Home Staff Who Have Been Vaccinated Against COVID-19 Varies Substantially by State

The share of nursing home staffers who have been fully vaccinated against COVID-19 varies considerably by state, from 70 percent in Ohio to 99 percent in Maine, Rhode Island, New York and Massachusetts, a new KFF analysis finds. The national average is 84 percent. The analysis of federal nursing home...

* * * *

Contents [click to move among sections]

::

Contents [click to move among sections]

:: [Coronavirus \[COVID-19\] - WHO](#)

:: [Emergencies](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

Milestones - **Perspectives**

:: [Coronavirus \[COVID-19\] - WHO](#)

:: [Emergencies](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2021. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health,

human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the Bill & Melinda Gates Medical Research Institute , [PATH](#), and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*